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Anemia, defined by the World Health Organization as hemoglobin <8 mmol/L in males and <7.5 
mmol/L in females, is highly prevalent among patients diagnosed with colorectal cancer.1, 2 
Typically, multiple factors contribute to the development of anemia in cancer patients, with iron 
deficiency as principal cause.3 Iron deficiency can be induced by chronic tumor-induced blood 
loss, resulting in an absolute iron deficiency, and impaired iron homeostasis, caused by systemic 
inflammation with increased hepcidin levels and resulting in functional iron deficiency. Finally, 
surgery-induced blood loss further aggravates the severity of anemia.
In patients awaiting surgery, anemia is commonly observed and more and more considered as an 
important health problem.4, 5 Anemia namely is found to be associated with increased postopera-
tive morbidity and mortality, increased duration of hospitalization, and reduced quality of life.6, 
7 Regarding colorectal cancer patients, preoperative anemia is also an independent prognostic 
factor for impaired long-term overall and disease-free survival.8-10 Correcting anemia, notwith-
standing the fact that the observed association should not be held equivalent to causality, has 
therefore become of main interest, not only to improve quality of life but possibly also survival.
Blood transfusions in earlier days were the default therapy to correct such anemia. The overall 
goal of transfusion is to treat or prevent the deficiency in oxygen delivery to body tissues. The 
major benefit of blood transfusion, as compared to other treatment modalities for anemia, is a 
rapid increase in hemoglobin (Hb) levels. Hence, blood transfusion is the only option for patients 
who require immediate correction of anemia. The first blood transfusions were attempted in 
the 17th Century, shortly after the English physician William Harvey discovered the circulation 
of blood. Although successful blood transfusions between animals had been observed, when 
transfusion of animal blood into humans, mostly to treat psychiatric illnesses, proved fatal, a ban 
on transfusions was installed by the pope. It was not until 1818 when James Blundell, a British ob-
stetrician, performed the first successful human-to-human blood transfusions for the treatment 
of postpartum hemorrhage. However, the undiscovered ABO blood group incompatibilities 
caused these blood transfusions to often show grave hemolytic transfusion reactions with severe 
morbidity and even mortality. Ever since, several vital discoveries, such as the ABO human blood 
groups by Karl Landsteiner in 1900, and the ability to anticoagulate and thus test and store blood, 
contributed largely to the present availability and safety of blood transfusions. Blood transfusions 
presently save many trauma and obstetric patients from exsanguination and enable complicated 
surgery and intensive hemato-oncologic treatments. 
In modern transfusion medicine in developed countries, the nowadays’ high level of safety in the 
transfusion chain, involving the entire process from donor recruitment to transfusion outcome, 
is evidenced by the low incidence of adverse events in the transfusion chain.11 However, aside 
from this low risk for adverse events, growing evidence suggests that the correction of anemia by 
blood transfusion is associated with increased postoperative morbidity and mortality.12, 13 In the 












specific context of colorectal cancer surgery, the use of perioperative blood transfusion was not 
only found associated with increased short-term postoperative morbidity, but, importantly, also 
with impaired long-term overall and disease-free survival, as already demonstrated by Busch et 
al in 1993.14 In a randomized controlled trial, Busch et al. demonstrated that regardless of their 
type (autologous or allogeneic), transfusions are associated with poor prognosis. Twenty years 
later, Harlaar et al. studied the long-term outcomes of this randomized controlled trial, demon-
strating that the patients did not benefit from autologous as compared to standard allogeneic 
transfusion. On the contrary, the overall and colorectal-cancer specific survival rates were worse 
in the patients in the autologous group.15 The causality of the association between blood transfu-
sions and long-term prognosis in colorectal cancer, as well as the potential causal mechanism, is 
being questioned and is still a major topic of discussion.16-18  
Red blood cell production is normally controlled by erythropoietin, a cytokine produced in 
the kidneys. Erythropoiesis-stimulating agents (ESAs) were therefore initially developed for 
the treatment of anemia in patients with chronic kidney disease. Later, in an attempt to avoid 
blood transfusion and eliminate the associated risks, ESAs were additionally used in cancer 
patients undergoing chemotherapy. ESAs indeed increased the Hb level in these patients, and, 
as a result, decreased the need for blood transfusions.19, 20 However, aside from these short-term 
advantageous effects, thromboembolic risks were also found associated with ESA treatment.21-
24 In addition, numerous randomized studies with ESA therapy in various types of cancer have 
shown a decrease in overall and disease-free survival.25-28 ESAs therefore are now contraindicated 
when the anticipated treatment outcome is cure. Hence, only in patients undergoing palliative 
treatment the use of ESAs may be considered.29
New approaches to optimize the preoperative hemoglobin level and thus reduce the blood 
transfusion requirement, however, remain of large interest and are collectively termed as patient 
blood management (PBM). In this regard, the effect of iron, and especially intravenous iron, is in-
creasingly being explored.30-32 While oral iron is the standard treatment for iron deficiency anemia 
since the 19th century, it also has significant disadvantages. It is known to be slow in terms of 
absorption rate, to potentially cause constipation, and, due to poor duodenal absorption caused 
by increased hepcidin production, to be largely ineffective in patients with inflammation and 
cancer. These side effects have led to the development of parenteral iron compounds, that indeed 
showed to be more effective in optimization of Hb level and to have less side effects. Presently, 
ferric carboxymaltose (Ferinject)33-35 and iron isomaltoside 1000 (Monofer)36 are most frequently 
used for intravenous iron administration. In the perioperative setting, the iron preparations can 
be administered as a single treatment of up to 1000 mg in a relatively short time, and the effect of 
such iron preparations is mostly studied in orthopedic and cardiac.37-39 However, presently, also in 
cancer surgery perioperative intravenous iron therapy is more and more considered while anemia 
in cancer patients is most frequently associated with iron deficiency.3 In the specific context of 
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colorectal cancer surgery, intravenous iron, as compared to oral iron, has been shown to be 
more effective in treating preoperative anemia and iron deficiency. However, most studies so far 
did not demonstrate intravenous iron to reduce the blood transfusion requirement and, more 
importantly, actually improve postoperative outcome.40, 41 As a result, the advantages and use of 
preoperative intravenous iron remain matter of debate in colorectal cancer patients. 
 
Whilst the short-term effects and safety of intravenous iron are increasingly reported, strikingly no 
data on the long-term oncological effects and safety are available. Possible long-term oncological 
effects of iron therapy, however, are of special interest for several reasons. First, the results of 
laboratory, epidemiological and animal studies have shown a crucial role of iron in promoting 
cancer development and cancer growth.42-47 Second, anemia of inflammation is believed to be 
a potentially defense strategy of the human body to limit the growth of tumor cells.48 Anemia of 
inflammation is characterized by both reduced duodenal iron uptake and the sequestration of 
iron into the reticuloendothelial system. As a result, there is a disturbance of iron homeostasis 
with subsequent limitation of the availability of iron for not only erythropoiesis, but also, and 
importantly, the growth of tumor cells. Third, and finally, corroborating evidence implicates that 
especially gastrointestinal cancer cells, likely by their original iron-absorbing nature, have an 
altered iron homeostasis.49 This altered iron metabolism is characterized by increased iron import 
and decreased iron export proteins, resulting in enhanced proliferation. 
Outline Of the thesis
Against the background described above, the general aim of this thesis was to evaluate the role 
of iron in anemic patients with solid cancer, with special attention to the long-term oncological 
effects of iron therapy in the preoperative setting. In this thesis, this role of iron is specifically 
studied in the context of colorectal cancer.
Colorectal cancer is the second most common malignancy in the Western world after non-mel-
anoma skin cancer.50 Patients with TNM stage I-III colorectal cancer (i.e. no distant metastases) 
are considered for curative treatment by surgical resection of the primary tumor.51 Partly because 
of advances in surgical techniques, coupled with effective (neo)adjuvant therapy), the five-year 
survival rate of colorectal cancer has increased to 64%.52 The main reason to study the role of 
iron in the specific context of colorectal cancer is because the effects of both anemia and blood 
transfusion are already extensively studied in this patient group. As anemia and blood transfusion 
appear to be strongly associated with adverse short and long-term outcome following surgery, 
the use of iron therapy has gained increased attention in this patient group.30, 40 Specifically in 
colorectal cancer patients awaiting elective surgery, this has led to an increased administra-
tion of iron, and specifically intravenous iron, with the aim of optimizing patient’s condition and 
improving the postoperative outcome.












In Chapter 2 the long-term prognostic value of preoperative anemia in colorectal cancer patients 
is assessed in a systematic review and meta-analysis. In Chapter 3 data on the prevalence 
and type of iron deficiency are reported. In addition, the prognostic value of iron deficiency is 
presented. Chapter 4 includes a national survey among gastroenterologists, surgeons, and anes-
thesiologists to assess the current preoperative blood management strategies in the Netherlands, 
and to identify preferences of different physicians in the treatment of preoperative anemia. In 
Chapter 5, the short-term effects of preoperative intravenous iron therapy, including change in 
hemoglobin level and postoperative complication and blood transfusion rate, are studied. In 
Chapter 6 the hypothesis that iron therapy, as treatment of anemia, may impair long-term tumor 
prognosis is discussed. The effect of preoperative intravenous iron therapy on long-term survival 
and tumor prognosis is presented in Chapter 7. Chapter 8  presents a general discussion of the 
overall results together with perspectives for further research. Finally, Chapter 9 and 10 contain 
the respective English and Dutch summary of the main findings in this thesis. 
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AbstrAct
Objective: to evaluate the long-term prognostic factor of preoperative anemia in colorectal 
cancer patients. 
background: anemia is frequently observed in colorectal cancer patients, with a case incidence 
of 30 to 67 percent. Besides an indicator of tumor-induced blood loss and inflammation, anemia 
in cancer is also suggested to be a cause of inferior outcome, possibly via worsening of tumor 
hypoxia. as surgery is likely to enhance anemia, the long-term prognostic value of preoperative 
anemia seems most interesting.   
Methods: Comprehensive searches were carried out in all relevant databases, including MeDLINe, 
embase and Web-of-Science. to include studies addressing overall survival, follow-up had to 
be at least 24 months or till death. For pooling of survival results, a mixed-linear (fixed-effects) 
model was fit to the reported hazard ratios (HRs) to calculate a pooled estimate and confidence 
interval.   
results: We included 12 studies comprising 3588 patients to estimate the association between 
preoperative anemia and overall survival (OS) and disease-free survival (DFS). In a fixed-effects 
meta-analysis of eight studies, including both colon and rectal cancer, preoperative anemia was 
significantly associated with poor OS (HR 1.56; 95% CI 1.30 to 1.88; p < 0.001). A meta-analysis of 
seven studies also showed that preoperative anemia was significantly associated with poor DFS 
(HR 1.34; 95% CI 1.11 to 1.61; p = 0.002).  Restricted to studies exclusively on colon cancer or rectal 
cancer, HRs for OS were 1.25 (95% CI 1.00 to 1.55; p = 0.05) and 2.59 (95% CI 1.68 to 4.01; p < 0.001), 
respectively, while HRs for DFS were 1.21 (95% CI 0.96 to 1.52; p = 0.11) and 1.61 (95% CI 1.18 to 
2.21; p = 0.003).  
conclusion: the present meta-analysis reveals the long-term prognostic value of preoperative 
anemia in colorectal cancer patients, most distinct in in rectal cancer patients. however, this meta- 
analysis is mainly based on retrospective studies with high heterogeneity. these results justify 
raised awareness about the impact of preoperative anemia on long-term survival.













Colorectal cancer is the third most commonly diagnosed cancer in men and second in women, 
accounting for more than 1.4 million new cases and 694 000 associated deaths per year 
worldwide.1 the primary treatment for patients with colorectal cancer is surgical resection of 
the primary tumor. Partly because of advances in surgery, coupled with effective (neo)adjuvant 
therapy, the five- year survival rate of colorectal cancer has increased to 64 percent.2
Anemia, defined by the World Health Organization as hemoglobin <13 g/dL in males and <12 g/
dL in females, is present in 30 to 67 percent of colorectal cancer patients at some point during 
the course of their disease.3 Contributing mechanisms to the development of anemia include 
tumor-induced blood loss and reduced iron uptake and utilisation due to IL-6 driven overexpres-
sion of hepcidin, known as anemia of chronic disease.4 Myelosuppressive chemotherapy and 
surgery-induced blood loss further aggravate the severity of the anemia.5 Besides a marker of 
more advanced tumor stage and treatment intensity, anemia in cancer is also suggested to be a 
cause of inferior outcome, possibly via worsening of tumor hypoxia.6 hypoxia has been linked to 
radiotherapy and chemotherapy resistance, as oxygen is essential for the cytotoxic activities of 
these treatments.7-9 Furthermore, by inducing proteomic and genomic changes, hypoxia may also 
increase the proliferative and metastatic potential.7
While surgical resection of the tumor, often the primary treatment for patients with colorectal 
cancer, is likely to abruptly intensify the anemia, we hypothesize that the long-term prognostic 
value of anemia in colorectal cancer patients is best studied with preoperative hemoglobin values. 
Several studies in patients undergoing surgery for colorectal cancer have described preoperative 
anemia to be a prognostic factor for decreased disease-free survival (DFS) and overall survival 
(OS),10-13 but no quantitative and comprehensive review examining the correlation between pre-
operative anemia and long-term survival has been published. the purpose of this systematic 
review and meta-analysis is to confirm the long-term prognostic value of preoperative anemia in 
patients with primary colorectal cancer. 
MethOds
all aspects of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
were followed.14
Literature search strategy
Comprehensive searches were carried out by a medical librarian in MeDLINe, embase, Web-of-sci-
ence, Scopus, Cochrane, CINahL, pubMed publisher, proQuest, Lilacs, Scielo and Google scholar. 
the search was performed on articles published through February 2016 relevant to the long-term 
prognostic value of preoperative anemia in patients with colorectal cancer. No publication year 
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or publication language restrictions were applied. Our overall search strategies included terms 
and alternative spellings for anemia (anemia, hemoglobin), preoperative (preoperative, pretreat-
ment, pre surgical, pre therapeutic), recurrence or survival (recurrence, survival, survival analysis, 
mortality, prognosis, risk factors, risk assessment, follow up, cohort), cancer (cancer, neoplasm, 
tumor, carcinoma, adenocarcinoma, malignancy), and colorectal (colorectal, large intestine, 
colon, rectum, bowel).
study selection
Studies were evaluated for inclusion by two independent researchers (MvH, MJW) for relevance 
to the subject.  Study selection was accomplished through three levels of study screening.  In 
level 1, the following types of studies were excluded: reviews, case-reports, letters, editorial, 
poster abstracts editorials, papers studying non-human. In level 2, abstracts were reviewed 
for relevance and full-text articles were obtained. to be considered relevant, abstracts had to 
describe (1) preoperative anemia or anemia-related parameters (hemoglobin, hematocrit) in 
patients with colorectal cancer, and (2) survival-related parameters (disease-free survival, cancer-
specific survival, overall survival, mortality). In articles addressing overall survival or mortality, 
follow-up had to be for at least 24 months or till death. In level 3, full text articles were reviewed for 
inclusion in qualitative and quantitative synthesis. any discrepancies in exclusion were resolved 
by discussion between the reviewers with supervision by MS. 
critical appraisal and data extraction
the methodological quality of the included studies was assessed according to the ‘Newcastle 
Ottawa Scale (NOS) for Cohort Studies’, which score selection, comparability, and outcome.
The following study details were extracted: first author, study type, sample size, definition 
anemia, therapy anemia, time measurement hemoglobin level, follow up, results survival analysis 
and hazard ratio (HR) with 95% CI. If HR was not reported, or if HR could not be estimated from 
reported data, attempts were made to contact the study authors for individual patient data. 
statistical analysis
the main outcomes were OS and DFS, comparing colorectal cancer patients with preoperative 
anemia, to those with no preoperative anemia. For pooling of survival results, a mixed-linear (fixed-
effects) model was fit to the reported HRs to calculate a pooled estimate and confidence interval. 
pooled hrs were calculated for both colon and rectal cancer mixed, and for colon and rectal 
cancer separated. If the study reported both univariate and multivariate results, the latter was 
used in the analysis. If these statistical variables were not made available in the article reporting 
them, hr was estimated from reported or given data using methods reported by tierney et al.15 
Tests of statistical significant were performed using the Z-test with α=0.05. Heterogeneity across 












studies was tested using I2 statistics. An I2 value more than 50% is recognized as significant het-
erogeneity. 
This research did not receive any specific grant from funding agencies in the public, commercial, 
or not-for-profit sectors
resuLts
the identification of eligible studies is shown in fig 1. A total of 803 studies were identified from 
the literature search and 431 studies remained after excluding duplicate articles. Three additional 
studies, agreed upon by both reviewers, were included after manually scrutinizing reference lists. 
Titles and abstracts of all identified studies were reviewed to exclude the clearly irrelevant ones. 
a total of 33 potentially relevant articles were read in full. Of 33 papers, 13 fell within the scope of 
the study and were included in the qualitative analysis.10-13, 16-24 the main characteristics of the 
13 eligible publications are shown in table 1. 
Figure 1. PRISMA flowchart
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For quantitative analysis, 12 studies were included.10-13, 16-21, 23, 24 In two studies both colon and 
rectal cancer patients were included, while five studies reported exclusively on colon cancer, and 
five studies reported exclusively on rectal cancer. In two studies 16, 23, hazard ratio (HR) could not 
be estimated from reported data, but patient-level survival data were provided by study authors, 
making it possible to include the studies in the quantitative analysis. One study was excluded 
because the hr could not be estimated from reported data and while patient-level data were not 
Figure 2. Forest plot of 8 evaluable studies assessing OS in colorectal cancer according to methods of analysis by a fixed-
effects model (above) and forest plot of 7 evaluable studies assessing DFS in colorectal cancer according to methods of 
analysis by a fixed-effects model (under). HR = hazard ratio, CI = confidence interval, IV = inverse variance (statistical 
method RevMan) 
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shared by the author.22 In the included studies, the prevalence of anemia varied between 18 and 
61%.
In figure 2, meta-analysis of eight studies, including colon and rectal cancer patients, demon-
strated that preoperative anemia was significantly associated with poor OS (HR 1.56; 95% CI 1.30 
to 1.88; p < 0.001; I2 = 82%). Among studies reporting HRs based on multivariate analysis, preop-
erative anemia was significantly associated with poor OS as well (HR 1.58; 95% CI 1.31 to 1.92; p < 
0.001; I2 = 86%). Two studies reporting HRs based on univariate analysis did not show significance 
for preoperative anemia (HR 1.39; 95% CI 0.77 to 2.51; p = 0.27; I2 = 76%) (figure 2). Preoperative 
anemia was also significantly associated with poor DFS (HR 1.34; 95% CI 1.11 to 1.61; p = 0.002; I2 
= 74%). When restricted to studies reporting multivariate HR, pooled HR was 1.25 (95% CI 0.98 to 
1.58; p = 0.07; I2 = 82%). Pooled HR for studies reporting univariate analysis was 1.49 (95% CI 1.10 
to 2.00; p = 0.009; I2 = 0%). 
Figure 3. Forest plot of 3 evaluable studies assessing OS in colon cancer according to methods of analysis by a fixed-
effects model (above) and forest plot of 4 evaluable studies assessing DFS in colon cancer according to methods of 
analysis by a fixed-effects model (under). HR = hazard ratio, CI = confidence interval, IV = inverse variance (statistical 
method Revman)
 












In meta-analysis of three studies including only colon cancer patients, preoperative anemia 
showed a near significant association with poor OS (HR 1.25; 95% CI 1.00 to 1.55; p = 0.05; I2 = 49%) 
(figure 3), while in meta-analysis of four studies addressing DFS, significance was clearly lacking 
(HR 1.21; 95% CI 0.96 to 1.52; p = 0.11; I2 = 84%) (figure 3). 
As shown in figure 4, in meta-analysis of four studies including only rectal cancer patients, preop-
erative anemia was significantly associated with poor OS (HR 2.59; 95% CI 1.68 to 4.01; p <0.001; I2 
= 0%). In three studies addressing DFS, pooled HR for preoperative anemia was 1.61 (95% CI 1.18 
to 2.21; p = 0.003; I2 = 27%) (figure 4). 
as shown in table 2, in subgroup analyses, including both colon and rectal cancer patients and 
when restricted to studies adjusting for age and tumor stage, pooled hrs for preoperative anemia 
 
Figure 4. Forest plot of 3 evaluable studies assessing OS in rectal cancer according to methods of analysis by a fixed-
effects model (above) and forest plot of 3 studies assessing DFS in rectal cancer according to methods of analysis by 
a fixed-effects model (under). HR = hazard ratio, CI = confidence interval, IV = inverse variance (statistical method 
Revman)
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in OS were 1.28 (95% CI 1.04 to 1.57; I2 = 0%) and 1.25 (95% CI 1.00 to 1.55; I2 = 49%). In DFS, 
pooled HRs for studies adjusting for age and tumor stage were 1.11 (95% CI 0.86 to 1.42; I2 = 79%) 
and 1.98 (95% CI 0.82 to 1.42; I2 = 86), respectively. In subgroup analyses based on the various 
definitions of anemia used by included studies, pooled HRs in OS and DFS were 1.56 (95% CI 1.28 
to 1.91; I2 = 89%) and 1.05 (95% CI 0.79 to 1.38; I2 = 84%) respectively, for studies using a restricted 
cut off defining anemia (<12 g/dL in female and <13 g/dL in male), as compared to pooled HRs of 
1.58 (95% CI 1.01 to 2.47; I2 = 58%) and 1.63 (95% CI 1.27 to 2.10; I2 = 39%) respectively, for studies 
using a more liberal cut off (>12 g/dL in female or >13 in male). 
In the quantitative analysis of specifically rectal cancer patients, two studies did report data on 
hemoglobin levels prior to or during neoadjuvant therapy, in contrast to 3 studies reporting data 
on directly preoperative hemoglobin level.  On average, neoadjuvant therapy was 5 weeks prior 
to surgery. In a sensitivity analysis in which the pooled hr was calculated for all studies, excluding 
the two studies reporting data on hemoglobin level prior to or during neoadjuvant therapy, 
pooled HR for preoperative anemia remained significant for OS (p = 0.0002; HR 2.40; 95% CI 1.52 
to 3.79) and DFS (p = 0.02; HR 1.49; 95% CI 1.07 to 2.07) and was almost equal in both OS and DFS 
compared to HR in main meta-analysis (OS; HR 2.59, DFS; HR 1.61).
Table 2: Main meta-analysis results




   Colorectal cancer
   Overall survival
      adjustment
         age 3 (Buunen Fjortoft, Lee) 1.28 (1.04-1.57) 0
         Stage 3 (An, Buunen, Fjortoft) 1.25 (1.00-1.55) 49
      Definition anemia (g/dL)
         <12 female and  <13 male 5 (Box, Buunen, Fjortoft, Qiu, Halteren) 1.56 (1.28-1.91) 89
         >12 female or >13 male 3 (An, Cengiz, Lee) 1.58 (1.01-2.47) 58
   Disease-free survival
      adjustment
         age 3 (Berardi, Buunen, Lee) 1.11 (0.86-1.42) 79
         Stage 3 (An, Berardi, Buunen) 1.98 (0.82-1.42) 86
      Definition anemia (g/dL)
         <12 female and  <13 male 3 (Berardi, Buunen, Peng) 1.05 (0.79-1.38) 84
         >12 female or >13 male 4 (An, Lee, Giessen, Giessen-Jung) 1.63 (1.27-2.10) 39













this meta-analysis shows that preoperative anemia is significantly associated with decreased 
long-term OS and DFS in patients with colorectal cancer. For colorectal cancer patients, separate 
subgroup analyses of studies with adjustment for important prognostic factors, such as age 
and tumor stage, showed that preoperative anemia is particularly associated with decreased 
long-term OS. However, since the effect of all confounding factors could not be assessed, a causal 
relationship cannot definitely be claimed. 
A difference was found in the prognostic value of preoperative anemia between colon and rectal 
cancer patients. Namely after subdividing colorectal cancer patients into colon and rectal cancer 
patients, our findings only apply to rectal cancer patients. In colon cancer patients, statistical 
significance is no longer present, however, a similar clear trend for preoperative anemia as 
a negative long-term prognostic factor is observed. as a whole, survival rates are known to be 
different for colon and rectal cancer patients, and different treatment strategies are required. In 
rectal cancer, particularly in stage 2 and 3, neoadjuvant chemoradiation therapy plays a pivotal 
role in treatment, whilst in colon cancer this is not the case. Furthermore, despite the lack of good 
quality comparative studies, in general, rectal cancer surgery is associated with longer operation 
time and more blood loss as compared to surgery for colon cancer.16, 25 hence, in rectal cancer, 
more extensive blood loss in these patients likely aggravates anemia even further. this condition 
therefore will increase the chance on hypoxia and hypoxia driven survival of remnant tumor mass 
and might explain a stronger association of preoperative anemia with long-term OS and DFS in 
rectal cancer patients than in colon cancer patients. In these respects, a separate analysis for 
colon and rectal cancer patients seems to be justified. 
In studying the prognostic value of preoperative anemia, gender should be preferably considered. 
In defining anemia distinction is made between male and female, and moreover, in colorectal 
cancer patients, sex differences in long-term survival are demonstrated. This is best known for the 
survival advantage of young and middle-aged female colorectal cancer patients with localized 
disease.26 Unfortunately, despite this known variation, in defining anemia only half of included 
studies used gender based anemia criteria, and the vast majority of studies failed to include 
gender in the analyses. as a result, gender could not be included in our subgroup analyses.
Meta-analysis in patients with other cancer types similarly showed that anemia, at any point 
during course of the disease, is associated with shorter survival. this was the case for patients 
with lung cancer, cervicouterine cancer, head and neck cancer, prostate cancer, lymphoma and 
multiple myeloma.27 anemia in this respect may be a common cause for treatment resistance, 
progression or even recurrence of cancer by several mechanisms, of which tumor hypoxia leading 
to an imbalance between oxygen supply and consumption receives most attention. experimen-
tal studies indeed showed that the oxygen supply to tumors is greatly reduced and hypoxia is 
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intensified at hemoglobin levels below 10–12 g/dl. Tumor hypoxia in its turn is known to reduce 
the effectiveness of both chemotherapy and radiotherapy, and can also negatively impact 
therapeutic outcome by causing a broad variety of proteomic and genetic changes, leading to 
increased metastatic potential.28 Moreover, under hypoxic conditions, the concentration of tran-
scription factor hypoxia-inducible factor 1 is increased and may stimulate hypoxia-inducible gene 
transcription resulting in metabolic, invasive and apoptotic changes; up regulation of vascular 
endothelial growth factor; and tumor angiogenesis.6, 29 
Results from experimental studies, showing that tumor hypoxia is intensified below hemoglobin 
levels 10-12 g/dl, may suggest that not every anemic condition will result in tumor hypoxia. 
However, when anemia is abruptly intensified by surgery, hypoxia driven survival of remnant tumor 
mass is likely important for eventual outcome. Our results from subgroup analyses based on the 
definition of anemia do not support the finding from experimental studies showing that tumor 
hypoxia, suggested to be the cause of inferior outcome, is intensified at decreasing hemoglobin 
levels. No trend was observed suggesting that lower hemoglobin levels are associated with worse 
long-term prognosis, however, high statistical heterogeneity was found in the various analyses. 
the reported association between anemia and survival might suggest that correcting the pre-
operative anemia might positively influence long-term survival of colorectal cancer patients. 
However, treatment modalities for correcting anemia may also negatively influence outcome. 
three principal options for treatment of anemia are to be considered, namely red blood cell trans-
fusions, erythropoiesis-stimulating agents (ESAs) and iron, but so far there is no solid evidence 
that correction of anemia would improve long-term tumor prognosis.
Blood transfusions are implicated to have immunomodulatory effects that could compromise 
wound-healing and pathogen control, and also the immune-surveillance against cancer.30 
especially in patients with colorectal cancer, blood transfusions have been reported to be 
associated with worse prognosis.31, 32 Interestingly, and refuting the immunomodulation of 
allogeneic blood transfusion, autologous blood transfusion showed no benefit as compared 
to standard allogeneic blood transfusion. From these studies, it was concluded that blood 
transfusion was not likely to modulate prognosis.33, 34 hence, a restrictive transfusion policy 
was implemented in favour for iron and erythropoiesis-stimulating agents (ESAs) therapy as 
transfusion sparing alternative. However, both these alternatives might not be indifferent for the 
prognosis of colorectal cancer either. 
Indeed, eSas reduce anemia and transfusion requirements in cancer patients. however, eSas have 
also been reported to worsen cancer prognosis.35-37 possible mechanisms by which eSas enhance 
tumor growth in general, and tumor recurrence in particular, is by increasing the production of 
pro-angiogenic factors, such as VeGF and by anti-apoptotic action.38 Increased serum VeGF is 












associated with decreased disease-free and overall survival in patients with advanced colorectal 
cancer. In current clinical practice, treatment with eSas should only be considered in patients 
with symptomatic chemotherapy-induced anemia and hemoglobin levels <10 g/dL. Moreover 
in patients treated with curative intent, eSas should be used with caution. however, available 
analyses of data from RCTs have not stratified results on the basis of treatment intent (i.e. palliative 
versus curative), and therefore, future research on this topic is warranted 39, 40
Similarly, iron therapy is reported to increase hemoglobin levels and with it reduction in allogeneic 
blood transfusion in patients with colorectal cancer.41, 42 however, iron is also known to be an 
essential nutrient for proliferating tumor cells, and anemia of chronic disease, characterized 
by adequate iron stage but insufficient iron supply for erythroblasts and other iron dependent 
tissues, is believed to be a potentially effective defense strategy of the human body to inhibit 
growth of tumor cells.4 Numerous studies support the hypothesis that both dietary iron and 
elevated iron levels increase the risk of colorectal cancer,43-45 and a relationship between levels of 
iron stores and cancer risk is suggested by studies showing that blood donation, which reduces 
body iron stores, is associated with lower cancer risk.46 this notion that iron therapy and high iron 
levels could pose a risk, is further enforced by the reversed, namely that systemic iron reduction 
by phlebotomy decreased the incidence of visceral malignancies and mortality in patients with 
peripheral arterial disease.47 Finally, several animal experiment studies show iron as a risk factor 
for developing colorectal cancer and tumor growth.48, 49 Clearly, while preoperative anemia is a 
risk factor for OS and DFS, to our knowledge, no study has addressed the long-term hazards of 
iron therapy in patients with colorectal cancer.
LIMItAtIOns
In this meta-analysis, next to 12 observational studies, one rCt was included. this rCt was 
not designed primarily to examine the effect of anemia, but HR of preoperative anemia could 
be computed from shared individual patient data. however, this was limited by the lack of 
information on anemia related factors, for example blood transfusion rates. 
anemia is associated with important prognostic factors as disease severity, and with treatment 
strategies, and thus with outcome itself. In this meta-analysis, to adjust for important prognostic 
factors, subgroup analyses of studies adjusting for age and tumor stage were performed. however, 
since the vast majority of the included studies were observational and of retrospective nature, many 
factors significantly associated with DFS and OS could not be corrected for. For example, blood 
management strategies themselves, like preoperative blood transfusion, eSas and iron therapy, 
all reduce anemia and should ideally be known and corrected for. Only in one study, the patients 
receiving blood transfusion were excluded, while in two studies, blood transfusion was adjusted for 
in the multivariate analysis. In these studies, the HRs for preoperative anemia differed greatly.
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additionally, a principal limitation to this study was the high level of statistical and clinical hetero-
geneity in the findings, likely due to the variety of populations studied and the different definitions 
of anemia used by included studies. Before including studies in the meta-analysis, a quality 
assessment was performed, which showed that the evidence of each individual study varied from 
high to very low. however, the study with the lowest quality assessment score did not provide 
sufficient data to include in the quantitative analysis. As the larger studies tended to be those 
conducted with more methodological rigour, a fixed-effects analysis was used. In this fixed-effects 
meta-analysis relatively more weight is rewarded to larger studies. This seems to be justified as 
results of the study with the most patients, addressing colon cancer, differed considerably from 
results of the other studies, particularly in the DFS. In general, the studies addressing rectal cancer 
were of less quality.
cOncLusIOn
the present systematic review and meta-analysis reveals the long-term prognostic value of preop-
erative anemia in colorectal cancer patients This finding is particularly the case for rectal cancer 
patients and is supported by subgroup analyses of studies adjusting for important prognostic 
factors, such as age and tumor stage. However, since the effect of all confounding factors could 
not be assessed, a causal relationship can still not be claimed. the results should be interpreted 
with care given the retrospective observational nature of the vast majority of included studies, 
with high levels of heterogeneity. this meta-analysis does not answer the intriguing question if, 
and to what extent, correction of anemia by blood transfusion, eSas or iron, will also modulate 
the outcome. Instead of improving survival, circumstantial evidence seems to indicate that these 
treatment modalities may even negatively influence long-term outcome. Future well designed 
rCts therefore have to prove the observed associations of our meta-analysis and have to provide 
evidence if the present preoperative blood management strategy for colorectal cancer patients is 
optimal and safe as regards to long-term outcome.
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AbstrAct
background: In preoperative blood management of colorectal cancer patients, intravenous iron 
therapy is increasingly used to treat anemia and prevent red blood cell transfusions. however, 
while iron deficiency is the most common cause of anemia, little is known about the prevalence 
and namely type of iron deficiency in this population, whereas both types of iron deficiency (i.e. 
absolute and functional iron deficiency) are recommended to be treated differently by interna-
tional cancer guidelines.
Objective: To investigate the prevalence and namely type of iron deficiency in colorectal cancer 
patients, and to assess its clinical relevance.
Methods: Preoperative iron status, clinical parameters (i.e. age, ASA classification, tumor 
location, tumor stage) and postoperative complications were retrospectively collected for all 
newly diagnosed colorectal cancer patients in our institution over a 3-year period. 
results: Iron deficiency was observed in 163 (48.1%) of 339 patients. Of these iron deficient 
patients, 3.7% had an isolated absolute iron deficiency (AID) and 15.3% a functional iron 
deficiency (FID), while the rest had a combination of AID and FID. Anemia was present in 66.1% of 
iron deficient patients. Iron deficiency was significantly associated with increased postoperative 
complication rate (univariable OR 1.94, p=0.03, multivariable OR 1.84, p=0.07), with right-sided 
tumors (p<0.001), high ASA classification (p=0.002), advanced tumor stage (p=0.01), and advanced 
age (p=0.04). In comparing clinical parameters between patients with AID and FID, advanced age 
was significantly associated with FID (p=0.03), and the presence of anemia with AID (p=0.02). 
conclusion: In preoperative colorectal cancer patients, there is a high prevalence of iron 
deficiency, including a high percentage of patients with - a component of - functional iron 
deficiency, associated with increased postoperative complication rate. As both types of iron 
deficiency require a different treatment strategy, our results illustrate the therapeutic potential 
of especially intravenous iron supplementation in patients with severe iron deficiency, and stress 
the urgency of routinely monitoring preoperative iron status and differentiation between types of 
iron deficiency. As iron therapy may also be potentially harmful in respect to stimulation of tumor 
growth, future clinical trials assessing the long-term effect of iron therapy are necessary.













preoperative anemia is frequently observed in colorectal cancer patients, with reported case 
incidences of >30 %.1 preoperative anemia generally is associated with increased postoperative 
morbidity and mortality,2 and is also reported to be a cause of inferior long-term outcome, possibly 
by worsening of tumor hypoxia.3, 4 Furthermore, preoperative anemia is associated with increased 
utilization of allogeneic red blood cell transfusion (RBC), which, for its part, is also associated with 
deleterious effects on the short- and long-term outcome in colorectal cancer patients.5, 6 
Iron deficiency (ID) is the most common cause of preoperative anemia in colorectal cancer 
patients.7 Contributing mechanisms to the development iron deficiency anemia include chronic 
tumor-induced blood loss and impaired iron homeostasis associated with chronic disease. While 
chronic blood loss will deplete iron stores and cause absolute iron deficiency (AID), functional 
iron deficiency (FID) is characterized by both reduced iron uptake in the gut and sequestration in 
the reticulo-endothelial system of absorbed iron, resulting in a reduction of biologically available 
iron.8 Next to AID, FID is the second most prevalent cause of anemia. FID is especially known from 
patients with immune activation and therefore termed as anemia of inflammation of anemia of 
chronic disease. 
The importance of this differentiation lies in the fact that the indication for initiation and the ad-
ministration route of iron therapy differs between AID and FID.9 In patients with AID, iron therapy is 
recommended to be started independently of the actual hemoglobin(Hb) level, while in patients 
with FID, iron therapy is advised only if patients are symptomatic because of iron deficiency 
and/or anemia and should be withheld in patients with high ferritin levels (i.e. >1000 ng/ml). In 
addition, in patients with FID, oral iron is poorly absorbed in the duodenum, while intravenous 
iron is more effective. On the other hand, restrictive iron therapy might be advisable for cancer 
patients in general, as iron is reported to stimulate tumor growth. the latter could be even more 
important for cancer patients with FID. This cancer-induced immune response namely might well 
protect against proliferation of tumor cells.8, 10 
Notwithstanding possible detrimental effects, iron in preoperative blood management to reverse 
the anemia associated prognosis has gained more attention.11 In particular, this has led to the 
increased use of preoperative intravenous iron supplementation. Whereas preoperative anemia 
is a well-known and frequent complication in colorectal cancer patients, little is known about the 
prevalence of iron deficiency.7, 12 Whilst research is being carried out on the efficacy of preopera-
tive oral and intravenous iron therapy in patients with iron deficiency anemia, no trials differenti-
ate between AID and FID and often only the Hb increase and reduction in RBC transfusions are 
studied.13, 14 
Despite the recommendations by international oncological guidelines,15, 16 routinely monitoring 
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preoperative iron status is often not standard of care, and is, for example, not incorporated into 
the Dutch guideline on the treatment of anemia in oncological patients. The aim of present study 
is to identify the prevalence and type of iron deficiency, and to assess the clinical relevance of iron 
deficiency.
MethOds
all patients undergoing resection for colorectal cancer between 1 July 2013 and 1 July 2016 at the 
Department of Surgery, Reinier de Graaf Hospital, were eligible for inclusion. In these patients, the 
inclusion criterion was the availability of iron status (i.e. iron, transferrin, transferrin saturation, 
ferritin), measured directly after colonoscopy and suspicion of colorectal cancer. Clinical and 
pathological data, including age, gender, ASA classification, tumor type, pathological tumor 
stage, neoadjuvant treatment and 30-day overall postoperative complications (i.e. pulmonic, 
cardiologic, thrombotic, infectious, neurologic) were collected by the Dutch Surgical Colorectal 
Audit (DSCA), a disease-specific national audit. This audit collects information on patient, tumor, 
treatment, and 30-day and in-hospital outcome characteristics of all patients undergoing a 
resection for primary colorectal carcinoma in the Netherlands. the data set is based on evidence-
based guidelines and is cross-checked on a yearly basis with data from the Netherlands Cancer 
Registry. In addition, hemoglobinvalues (i.e. at diagnosis, preoperative and postoperative), and 
iron status at diagnosis, were retrospectively collected.
According to the World Health Organisation (WHO), anemia was defined as Hb <8 mmol/L in men 
and <7.5 mmol/L in women. Iron deficiency was defined as transferrin saturation (TSAT) <20% 
and was further classified as absolute iron deficiency (AID), functional iron deficiency (FID), or a 
combination of both conditions. AID was defined as TSAT <20% and increased transferrin (>3.6 
g/L); FID as TSAT <20%, reduced to normal transferrin and increased ferritin (>200 μg/L). 
Tumor locations were classified as right colon (i.e. cecum, colon ascendens, hepatic flexure), 
transverse colon, left colon (i.e splenic flexure, colon descendens, sigmoid) and rectum. Tumor 
staging and tumor grading was determined according to the AJCC recommendations in colorectal 
cancer, and was given by pathologic examination. The ASA physical status classification system 
was used for assessing the fitness of patients before surgery.
The results are mainly illustrated by descriptive statistics. χ2, Fisher’s exact and Student’s t 
test were used to compare the frequencies of both categorical and continuous variables with 
iron status (i.e. iron deficiency versus non-iron deficiency, and absolute versus functional iron 
deficiency) and tumor location (i.e. colon versus rectum). Binary logistic regression analysis was 
performed to identify the relationship between iron deficiency at diagnosis and postoperative 
complication. all variables in the univariable analysis were included in the multivariable analysis. 
A significance level of 0.05 was considered to be statistical significant.












Approval by the Local Medical ethics Committee was obtained. Our institution, a teaching 
hospital, is making use of opt-out consent.  each included patients had given consent by not 
declining to give consent.
results
Incidence of iron deficiencies
In total, 429 patients underwent surgery for colorectal cancer, and iron status was available in 
339 patients (all measured at diagnosis). Table 1 shows the baseline characteristics of included 
patients. The mean age at presentation was 69.6 (range 28-95); 185 males and 154 females were 
included. Most patients (58.1%) were classified as ASA 2 and the most frequent site of tumor 
occurrence was the left colon (36.6%), followed by the rectum (29.5%), right colon (25.4%) 
and transverse colon (8.6%). The majority of patients were classified as pTNM stage 2 (33.6%), 
followed by stage 1 (29.8%), stage 3 (28.0%), stage 4 (8.6%). Of 339 patients, preoperatively, 35 
patients (10.3%) received radiotherapy alone, 19 patients (5.6%) received concomitant chemo-
radiotherapy, and 8 patients (2.4%) received chemotherapy alone. In total, 256 patients (79.0%) 
were symptomatic at presentation; most patients presented with blood loss (n=108), followed by 
change in stool (n=72), other (n=43)(i.e. abdominal pain, weight loss, fatigue), and anemia (n=33). 
Iron deficiency was observed in 163 patients (48.1%), and anemia in 115 patients (33.9%). Among 
these iron deficient patients, 6 (3.7%) and 25 (15.3%) patients were absolute and functional iron 
deficient, respectively. In the majority of patients (n=132; 81.0%), iron deficiency was caused by 
a combination of AID and FID. In total, 80% of anemic patients had some form of iron deficiency 
(5.2% AID, 9.6% FID, 65.2% combination AID and FID). Of non-anemic patients, 14 (6.3%) were 
functional iron deficient, and 57 (25.4%) had a combination of AID and FID; no patients were 
absolute iron deficient (figure 1).
Associations between iron deficiency and patient and tumor characteristics
In table 2, the proportion of patients with and without iron deficiency are given in relation to 
gender, age, ASA classification, tumor location, pTNM stage, and the presence of anemia. Iron 
deficiency was significantly more likely to occur in the right colon (p <0.001), in patients with a 
more advanced pTNM stage (p=0.01), and in patients with a higher ASA classification (p=0.002), 
and in patients with more advanced age (p=0.043). Moreover, anemia was significantly more 
observed in iron deficient patients (p <0.001). Gender did not show a significant association with 
the presence of iron deficiency. Iron deficient patients presented more often in the workup of 
anemia, as compared to non-iron deficient patients (16.2% versus 4.7%), while non-iron deficient 
patients more often were diagnosed due to the screening program.
In table 3, the mentioned variables (i.e. gender, age, tumor location, ASA classification, pTNM 
stage and anemia) were compared between patients with AID and those with FID. Results showed 
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Table 1. Patient baseline characteristics (n=339)  
 n %
Gender
   male 185 54.6
   female 154 45.4
Age (years)
   mean (range) 69.63 (28-95)
ASA classification
   I 76 22.4
   II 197 58.1
   III 65 19.2
   IV 1 0.3
tumor location
   right colon 86 25.4
   transverse colon 29 8.6
   left colon 124 36.6
   rectum 100 29.5
Neoadjuvant treatment
   chemotherapy 8 2.4
   radiotherapy 35 10.3
   concomitant chemoradiotherapy 19 5.6
   none 277 81.7
pTNM stage*
   I 101 29.8
   II 114 33.6
   III 95 28.0
   IV 29 8.6
presenting symptoms
   asymptomatic (population screening) 68 21.0
   symptomatic 256
      blood loss    108    33.3 
      change in stool    72    22.2
      workup of anemia    33    10.2
      other    43    13.3
   unknown 15
Iron deficiency
   no 176 51.9
   yes 163 48.1
      absolute iron deficiency 6    3.7
      functional iron deficiency 25    15.3
      both conditions 132    81.0
anemia at presentation
   no 224 66.1
   yes 115 33.9
      absolute iron deficiency    6    5.2
      functional iron deficiency    11    9.6
      both conditions    75    65.2
* after chemo and/or radiotherapy in 62 patients












that advanced age was significantly associated with FID (p=0.03), while the presence of anemia 
was significantly associated with AID (p=0.02). Gender, tumor location, ASA classification and 
pTNM stage were not found to have any significant relationship with AID or FID.
Association between iron deficiency and postoperative complication
In table 4, the association between iron deficiency and postoperative complications is assessed 
by uni- and multivariable logistic regression analysis. In total, postoperative complications 
were observed in 75 of 339 patients. Initially, in univariable analysis, the categorical variable of 
severity of iron deficiency was included (i.e. no iron deficiency versus mild iron deficiency (TSAT 
<20%) versus severe iron deficiency (TSAT <10%)). As merely severe iron deficiency appeared to 
be significantly associated with postoperative complications (OR 1.92, p=0.045, versus mild iron 
deficiency OR 0.97, p=0.92), severe iron deficiency was included in uni- and multivariable logistic 
regression analyses, as shown in table 4. In univariable analysis, severe iron deficiency was signifi-
cantly associated with postoperative complications (OR 1.94, p=0.030). No significant result was 
found in multivariable analysis (OR 1.84, p=0.074).
Distinction between colon and rectum tumors
In table 5, the different variables between colon and rectum tumors are shown. Anemia, both 
Figure 1. Prevalence of iron deficiency
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Table 2: Characteristics non-iron deficiency versus iron deficiency 
 Non-iron deficiency Iron deficiency p-value
Number, n (%) 176 163
Gender, % 0.13
   male 58.5 50.3
   female 41.5 49.7
Age (years) 0.043
   mean ±SD 68.5 ±10.86 70.8 ±10.56
ASA, % 0.002
   I + II 86.9 76.3
   III + IV 13.1 26.4
Tumor location, % <0.001
   right colon 13.6 38
   transverse colon 8.5 8.6
   left colon 39.8 33.1
   rectum 38.1 20.2
pTNM stage, % 0.01
   I 36.9 22.1
   II 27.3 40.5
   III 28.4 27.6
   IV 7.4 9.8
Anemia at diagnosis, n (%) 23 (13.1) 92 (56.4) <0.001
Presenting symptoms, n (%) <0.001
   asymptomatic 47 (27.6) 21 (13.6)
   symptomatic 123 133
      blood loss    60 (35.3)    48 (31.2)
      change in stool    41 (24.1)    31 (20.1)
      workup of anemia    8 (4.7)    25 (16.2)
      other    14 (8.2)    29 (18.8)  
at diagnosis, preoperative and postoperative, was more prevalent in colon tumors (p <0.001, p 
<0.001, p=0.04, respectively). Reduced Hb levels at diagnosis, preoperative and postoperative 
were found to be significantly associated with colon tumors (all p <0.001), while a reduction in 
the hb level due to surgery was more pronounced in patients with rectum tumors as compared to 
those with colon tumors (1.09 mmol/L versus 0.96 mmol/L, p=0.05). Mean duration from diagnosis 
to surgery was 7.4 weeks for all colorectal tumors, but was significantly different for colon cancer 
patients (5.1 weeks) as compared to patients with rectum cancer (12.2 weeks).












 Absolute iron deficiency Functional iron deficiency p-value
Number, n 6 25
Gender, % 0.79
   male 66.7 72
   female 33.3 28
Age (years) 0.03
   mean ±SD 68.5 ±4.23 74.2 ±7.40




   I + II 66.7 80.0
   III + IV 33.3 20.0
pTNM stage, % 0.66
   I + II 66.7 52.0
   III + IV 33.3 48.0
Anemia, % 0.02
   no 0 56.0
   yes 100 44.0
Table 3. Characteristics in absolute versus functional iron deficiency
Table 4. Univariable and multivariable logistic regression analysis for risk factors of postoperative complications 
 univariable   multivariable
 OR 95% CI p-value  OR 95% CI p-value
Age (years) 1.02 0.99 - 1.05 0.074 1.01 0.99 - 1.04 0.336
Gender 
   female versus male 0.38 0.22 - 0.67 0.001 0.38 0.21 - 0.68 0.001
ASA-classification
   III-IV vs. I-II 2.08 1.15 - 3.76 0.016 1.71 0.87 - 3.36 0.118
Surgery
   laparoscopic versus open 0.34 0.17 - 0.68 0.002 0.29 0.13 - 0.62 0.002
tumor localisation
   rectum vs. colon 1.47 0.86 - 2.53 0.16 2.07 1.12 - 3.82 0.021
Severe iron deficiency at diagnosis 1.94 1.07 - 3.54 0.030  1.84 0.94 - 3.60 0.074
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 colon rectum p-value
Number, n 239 100
Age (years) 0.15
   mean ±SD 70.2 ±10.4 68.3 ±11.6
Anaemia at diagnosis, % 41.8 15.0 <0.001
Preoperative anaemia, % 45.1 20.6 <0.001
Postoperative anaemia, % 76.2 65.0 0.04
Hb at diagnosis*
   mean ±SD 7.78 ±1.4 8.54 ±1.0 <0.001
preoperative hb
   mean ±SD 7.87 ±1.2 8.45 ±0.9 <0.001
postoperative hb
   mean ±SD 6.91 ±1.1 7.34 ±0.9 <0.001
reduction in hb level due to surgery
   mean ±SD 0.96 ±0.6 1.09 ±0.5 0.05
* in mmol/L
Table 5. Characteristics in colon versus rectum cancer patients 
dIscussIOn
the present study firstly shows a high prevalence of preoperative ID in colorectal cancer patients. 
Almost half of the patients with newly diagnosed colorectal cancer are iron deficient at pres-
entation. Interestingly, most patients have isolated FID (15%) or a combination of FID and AID 
(81%), compared to only 4% with isolated AID. From these results, we may conclude that the 
high percentage of patients with FID or a component of FID suggests that inflammation plays 
an important role in the development of iron deficiency in colorectal cancer patients. Secondly, 
patients with an advanced tumor, advanced age, a tumor in the right colon, and a high ASA clas-
sification, are more prone to develop iron deficiency. Thirdly, iron deficiency clearly plays a role 
in 80% of anemic patients (5.2% AID, 9.6% FID, 65.2% combined AID and FID), however, iron 
deficiency is also encountered in 32% of non-anemic patients (6.3% FID, 25.4% combined AID 
and FID).












In addition to the high prevalence of iron deficiency, the clinical relevance of iron deficiency is 
studied in the present study. Particularly, in univariable analysis, severe iron deficiency is signifi-
cantly associated with increased postoperative complication rate. Despite the fact that in present 
cohort loss of significance is observed in multivariable analysis, most likely due to the relative 
small sample size, iron deficiency still seems to be independently associated with postopera-
tive complications. Previous published studies namely have demonstrated the efficacy of pre-
operative iron supplementation with regard to reduction of the need for blood transfusion and 
reduction of hospital length of stay 17, 18. In addition, lower total numbers of postoperative compli-
cations were found. These results implicate iron deficiency as an attractive treatment target to at 
least ameliorate short-term outcomes. 
preoperative anemia is emerging as an important health problem in colorectal cancer patients. 
Importantly, preoperative anemia has already been associated with increased short-term post-
operative morbidity and mortality (<30 days)2, 19, and worse colorectal tumor prognosis3, 4, 20. 
Whereas preoperative anemia is often associated with iron deficiency, up to now, guidelines for 
the management of cancer or chemotherapy-induced anemia make only a few remarks on the 
management of iron deficiency.
The ASCO (American Society of Clinical Oncology) guideline21 on the use of epoetin and darbe-
poietin in adult patients with cancer recommends to only start iron supplementation in order to 
improve the efficacy of erythropoietin-stimulating agents (eSAs), and to monitor iron status during 
the course of eSA therapy. The eSMO (european Society for Medical Oncology) guideline16 states 
that intravenous iron therapy is more effective in terms of Hb optimisation as compared to oral 
iron therapy, and that iron therapy seems to reduce the total number of patients receiving blood 
transfusions. Most elaborate is the NCCN (National Comprehensive Cancer Network) guideline15 
on cancer- and chemotherapy-induced anemia that recommends to start iron monotherapy in 
absolute iron deficiency patients, independently of the presence of anemia, to start iron therapy 
in patients receiving eSA, and to withheld iron therapy in patients with active infections. The 
NCCN guideline additionally briefly addresses treatment of merely iron deficiency in non-anemic 
patients. This seems to be clinically relevant as iron deficiency itself, in the absence of anemia, 
can cause symptoms as impaired physical function and fatigue.22, 23 the observed high prevalence 
of iron deficiency in colorectal cancer patients causes the authors to advise routinely monitoring 
of preoperative iron status.
In general, guidelines and literature stress the high therapeutic potential of iron therapy in 
patients with iron deficiency anemia to increase preoperative hemoglobinlevel, to lower the need 
for blood transfusions and to improve short-term postoperative outcomes. an important caveat 
raised by eSMO is that oral - as opposed to intravenous - iron administration is quite ineffective 
in, as our study shows, the major part of patients that have some form of FID. Inflammation- 
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related IL-6 increased hepcidin production namely hampers iron absorption from the duodenum.8, 
24 Furthermore, there is an increased uptake and retention of iron in macrophages, resulting in 
limitation of availability of iron for iron-restricted erythropoiesis.
Notwithstanding its increased efficacy, timing and dosing is crucial for intravenous iron therapy. 
Maximal Hb response namely usually takes four to six weeks,25 while often more than one dose, 
maximum of 1 gram weekly (i.e. Ferinject or Monofer), is required. As highlighted in our study, 
such an approach is well feasible for patients with rectum tumors, however, for patients with 
colon tumors with only on average a 5-week period between diagnosis and surgery, this would 
be quite a challenge. Furthermore, preoperatively, anemia was found in almost half of all colon 
cancer patients, compared to only 20% of rectum cancer patients. However, surgery mediated 
blood loss and decrease in hb level was substantially higher in rectum cancer patients, with an 
increase in postoperative anemia to 66%, compared to 77% in colon cancer patients. This finding 
suggests that an even more proactive approach to correct preoperative anemia in all rectal 
cancer patients seems to be warranted.
An additional comment, however, should be made. Despite the increased use and success of 
preoperative - often intravenous - iron therapy to correct anemia, there are no clinical studies 
addressing long-term effects of iron therapy in colorectal cancer patients. The importance of this 
is highlighted by the fact that iron is an important growth factor for rapidly proliferating cells 
including bacteria and tumor cells. FID in this regard is believed to be a potentially effective 
defense strategy of the human body to inhibit the growth of pathogens. Several experimental 
animal studies have shown that exposure to iron can be a risk factor for developing colorectal 
cancer and tumor growth.10, 26, 27 While oral iron might induce intraluminal tumor growth, 
intravenous iron could in this respect additionally be a potential risk for stimulating growth of 
metastases. 
Ultimately, in preoperative blood management, the potential risks of blood transfusion and 
iron supplementation have to be cautiously weighed up against the risks of anemia and iron 
deficiency. Importantly, concerning oncological patients, not only short-term, but also long-term 
oncological effects have to be included in this risk assessment. Preoperative anemia and blood 
transfusion have already been strongly associated with a worse oncological outcome 5, 28. the 
oncological effects of iron supplementation, however, have not been studied yet. Therefore, 
clinical studies comparing the long-term effects of anemia and iron deficiency with the long-term 
effects of iron supplementation and blood transfusion are required to establish the optimal blood 
management strategy in oncological patients.
Strengths and limitations
One of the strengths of the present study is the timing of measuring iron status of patients. Iron 
status was measured directly after colonoscopy, where a lesion suspicious of colorectal cancer 












was noticed. As a result, in the vast majority, the iron status we used was not yet affected by any 
iron supplementation and therefore a reliable representation of condition around diagnosis. the 
major limitation of this study was the sample size. Therefore, in comparing characteristics of AID 
and FID, and in assessing the association between iron deficiency and postoperative complica-
tion, the small sample size did not allow us to draw firm conclusion on associations. In addition, 
Nonetheless, up till now, this is the largest group of colorectal cancer patients in which the 
prevalence and type of iron deficiency is described. 
cOnclusIOn
this study shows a high prevalence of preoperative iron deficiency in colorectal cancer patients, 
including a high percentage of patients with - a component of - functional iron deficiency, and 
frequently associated increased postoperative complication rate, anemia, right-sided colon 
tumors, advanced age and tumor stage, and poor physical status. As both types of iron deficiency 
require a different treatment strategy, our results illustrate the therapeutic potential of especially 
intravenous iron supplementation in patients with severe iron deficiency, and stress the urgency 
of routinely monitoring preoperative iron status and differentiation between types of iron 
deficiency. As iron therapy may also be potentially harmful in respect to stimulation of tumor 
growth, future clinical trials assessing the long-term effect of iron therapy are necessary.
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AbstrAct
background: preoperative anemia  is associated with increased postoperative morbidity and 
delayed recovery in oncological patients. In the treatment of such anemia , iron suppletion can 
replace blood transfusion and erythropoiesis-stimulating agents, which both have been associated 
with substantial side effects and increased risk of cancer recurrence. The aim of this study was to 
assess the efficacy of preoperative intravenous iron infusion in optimising hemoglobin (Hb) level 
in anemic colorectal cancer patients and to identify patient characteristics that are associated 
with an increase in Hb level after iron infusion. 
Methods: a retrospective cohort study was performed on patients who underwent surgery 
for colorectal cancer between 2010-2016 in a single teaching hospital. the primary outcome 
measure, the change in hemoglobin level, was assessed by comparing anemic patients receiving 
usual care (UC)(i.e. no iron therapy and no blood transfusion) with anemic patients receiving 
intravenous iron (IV) therapy (no blood transfusion). In addition, in assessing the association 
between intravenous iron therapy and postoperative blood transfusions and complications, all 
anemic patients were included in logistic regression analyses. 
results: 758 patients with colorectal cancer were eligible, of which 318 (41.9%) were anemic. The 
IV and the UC group included 52 and 153 patients with mean Hb levels at diagnosis of 6.3 and 
6.9 mmol/L, respectively. In the IV group, preoperative Hb level was significantly increased as 
compared to UC group (0.65 mmol/L vs 0.10 mmol/L, p<0.001). High increase in Hb level after iron 
infusion was associated with initial higher transferrin and lower ferritin levels (high versus poor 
responders: median transferrin 2.9 vs 2.7 g/L, median ferritin 12 vs 27 μg/L). Multivariable logistic 
regression analyses on all anemic patients (n=318) showed that administration of intravenous 
iron therapy did not affect postoperative blood transfusion and complication rate (OR 0.54, 
p=0.14 and OR=0.91, p=0.77, respectively).  
Discussion: Based on this cohort study, implementation of intravenous iron therapy in anemic 
colorectal cancer patients leads to a distinct increase of preoperative hemoglobin level. 
Intravenous iron therapy is most effective in patients presenting with more severe anemia, 
and with higher transferrin and lower ferritin levels, markers for an absolute iron deficiency, as 
compared to functional iron deficiency. Our finding, that the distinct Hb increase did not coincide 
with an expected decrease in the percentage of patients with a postoperative blood transfusion 
or complication, should be viewed with caution due to the retrospective nature of this study. 
Future randomised trials are thus required to establish the short-term benefits.













Colorectal cancer is the third most commonly diagnosed cancer in men and second in women 
worldwide1, and patients present with anemia  in up to a third of the cases.2 anemia  in this respect 
is emerging as an important health problem. It is not only associated with fatigue3, impaired 
physical performance and cognitive function, but most importantly also with increased morbidity 
and mortality.4-6 
Iron deficiency (ID) is the most common cause of preoperative anemia  in colorectal cancer 
patients.7 Contributing mechanisms to the development of iron deficiency anemia  (IDA) include 
chronic tumour-induced blood loss and also impaired iron homeostasis associated with chronic 
disease. While chronic blood loss will cause absolute iron deficiency (AID), characterized by 
depleted iron stores, impaired iron homeostasis will cause functional iron deficiency (FID), char-
acterized by reduced iron uptake and iron mobilisation from the reticulo-endothelial system, 
both leading to a reduction of biologically available iron for erythropoiesis.8 
enhancement of a patient’s condition prior to surgery has been gaining attention ever since the 
beneficial outcomes of such protocols were shown.9, 10 More specifically, normalization of pre-
operative hemoglobin (Hb) level by blood management strategy is an important element in this 
spectrum of preoperative care.11-13
The high prevalence of IDA in colorectal cancer patients provides an opportunity to optimise pre-
operative hemoglobin level by preoperative iron supplementation with the purpose of reducing 
the use of blood transfusions and erythropoiesis-stimulating agents (ESAs).14 avoiding blood 
transfusions and ESAs in oncological patients seems important because of its association with 
an increased risk of cancer recurrence and increased mortality15-17. Oral iron has been shown to 
correct anemia , but is also known to be slow in terms of absorption rate, to cause constipation, 
and to be ineffective in patients with FID as oral iron is poorly absorbed in the duodenum in these 
patients, due to increased production of hepcidin. 
Therefore as compared to oral iron, intravenous iron therapy is likely to be more effective in 
treating anemia , as shown in patients undergoing orthopedic18 or general abdominal surgery19. 
Based on these advantages, over the course of the last five years administration of intravenous 
iron has also been introduced in our institution. In this study, we retrospectively compare preop-
erative intravenous iron with usual care (i.e. no iron therapy) in anemic colorectal cancer patients, 
with regard to increasing preoperative hemoglobin level, and reducing postoperative complica-
tions and blood transfusions. In addition, predictive factors of good response to intravenous iron 
therapy will be studied. 
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MethoDs
Patient selection  
all patients undergoing resection for colorectal cancer between 1 January 2010 and 1 July 2016 at 
the Department of Surgery, Reinier de Graaf Hospital, the Netherlands, were identified. Patients 
who had surgery in the emergency setting, and those with missing data with respect to baseline 
hb levels and blood transfusions were excluded.
outcome Measures 
primary outcome was the change in hemoglobin level (i.e. Hb at diagnosis – Hb preoperative), 
secondary outcomes included the percentage of patients with a blood transfusion and complica-
tion <30 days postoperatively. 
Defining Patient Groups
Consecutive patients diagnosed with anemia  (men Hb <8.0 mmol/L, 12.9 g/dL; women Hb <7.5 
mmol/L, 12.0 g/dL) were eligible for inclusion. Initially, to provide a clear overview, the total 
anemic cohort was divided in two main groups (IV versus UC). 
The UC group consisted of patients receiving usual care, defined by no intravenous iron therapy 
<6 weeks prior to surgery. In general and following the disadvantages of oral iron suppletion, none 
of the patients awaiting surgery in our center did receive preoperative oral iron therapy. according 
to the criteria of the Dutch Blood Transfusion Guideline, during the entire study period, a blood 
transfusion was given according to the 4-5-6 rule, depending on the severity of the anemia  and 
the condition of the patient.20 
The IV group consisted of patients receiving intravenous iron therapy <6 weeks prior to surgery, 
defined by a dose of 1000-2000mg iron(III)carboxymaltose (Ferinject) or iron(III)isomaltoside 
(Monofer).  In our institution, a patient blood management protocol (PBM) was implemented in 
July 2013. prior to implementation of this protocol, treatment of preoperative anemia  was heavily 
depending on the interest in, and knowledge of PBM of each physician. As a result, there was het-
erogeneity in the cohort of anemic patients treated with intravenous iron therapy before July 2013. 
As part of the implemented PBM protocol, iron status was measured in all consecutive patients 
diagnosed with colorectal cancer and treatment with intravenous iron therapy was considered for 
patients with anemia . However, each physician did have the possibility to deviate from the PBM 
protocol, depending on their clinical assessment. as a result, there was also heterogeneity in the 
cohort of anemic patients treated with intravenous iron therapy after July 2013. Due to this hetero-
geneity, comparing a before- and after July 2013 cohort would not yield relevant results.
In addition, two subgroups (IV vs UC) were formed, in which all factors possibly directly affecting 












Hb level (i.e. preoperative blood transfusion and neoadjuvant chemotherapy) were excluded. 
Patients receiving their first intravenous iron infusion <7 days prior to surgery (IV group), and 
patients receiving intravenous iron infusion between 6 and 12 weeks prior to surgery (UC group) 
were additionally excluded.
statistical Analyses  
to assess the primary outcome, the difference between Hb level at diagnosis and preoperative 
hb level were calculated and analysed in the two subgroups. In addition, predictive factors of 
good response to intravenous iron were identified. For comparison, χ2 and Mann Whitney U tests 
were performed. to assess the association between intravenous iron therapy and postopera-
tive blood transfusion and complication, all anemic (i.e. UC + IV group) patients were included in 
uni- and multivariable logistic regression analyses. amongst the variables included in the logistic 
regression analyses is timeframe surgery (2014-2016 vs. 2010-2013), because in the course of time 
new surgical techniques or procedures could potentially contribute to a decrease in the postop-
erative blood transfusion and complication rate.  A significance level of 0.05 was considered to be 
statistical significant.
Data collection   
the use of preoperative intravenous iron therapy and pre-, peri-, and postoperative blood 
transfusion was retrospectively collected. In this respect, preoperative period was defined as 
<6 weeks before surgery, and postoperative period as <30 days after surgery. In addition, Hb 
values at diagnosis of colorectal cancer, preoperative (i.e. one day before surgery) and postop-
erative (i.e. one day after surgery) were manually obtained from medical records. Clinical and 
pathological data, including age, gender, ASA-classification (i.e. American Society of Anesthesi-
ologists physical status classification), overall comorbidities (i.e. cardiologic, vascular, diabetes, 
pulmonic, neurologic, thrombotic, urologic, musculoskeletal, infectious, malignancy, endocrine) 
tumor type, pathological tumor stage, neoadjuvant treatment, and postoperative overall com-
plications (i.e. pulmonic, cardiologic, thrombotic, infectious, neurologic) were collected by the 
Dutch Surgical Colorectal Audit (DSCA), a disease-specific national audit.21 this audit collects 
information on patient, tumour, treatment, and 30-day and in-hospital outcome characteristics 
of all patients undergoing a resection for primary colorectal carcinoma in the Netherlands. The 
data set is based on evidence-based guidelines and is cross-checked on a yearly basis with data 
from the Netherlands Cancer Registry.
Ethical approval for this study was provided by the Ethical Committee METC Zuidwest Holland 
(METC-nr 16-012, approved by secretary mw. drs. E. Roep, date of approval 03/02/2016). Our 
institution, a teaching hospital, is making use of opt-out consent.  Each included patients had 
given consent by not declining to give consent. 
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results  
In total, 916 patients underwent surgery for colorectal cancer. A total of 158 patients were 
excluded because of missing data on blood transfusion or hb level at diagnosis, or surgery in 
the emergency setting. A total of 318 patients (41.9%) were anemic at diagnosis, of which 94 
patients received intravenous iron treatment and 224 patients received usual care. After excluding 
all factors possibly directly affecting Hb level, 52 and 153 patients remained in the IV and UC 
subgroup (figure 1).
IV versus uc, total anemic cohort 
an overview of the baseline characteristics is presented in table 1. Both groups had a mean age 
above 70 years (IV=71.8 ±11.1, UC=73.7 ±9.9, p=0.15). In the UC group, the majority was male as 
compared to the IV group (58.5% vs 44.7%, p=0.02) and there were more patients with comorbidity 
(87.1% vs 79.8%, p=0.01) and with a rectum tumor (20.5% vs 5.3%, p=0.001). Regarding physical 
condition, surgical procedure and tumor stage, no significant differences were found. In the IV 
group, Hb level at diagnosis was significantly lower (6.12 mmol/L vs 6.61 mmol/L, p<0.001) and 
more patients received a preoperative blood transfusion (31.9% vs 12.9%, p<0.001). Out of 30 IV 
patients additionally receiving a preoperative blood transfusion, 13 patients (mean Hb level at 
diagnosis of 5.7 mmol/L) received blood transfusion prior to iron infusion, while in 17 patients 
Figure 1. Flow diagram












 IV group  (n=94) UC group (n=224) p-value
Age (years mean, SD) 71.8 ± 11.1 73.7 ±9.9 0.15
Gender (male) (%) 42 (44.7) 131 (58.5) 0.02
ASA-classification 0.06
   I-II 71 (75.5) 145 (64.7)
   III-IV 23 (24.5) 79 (35.3)
Comorbidity (overall) (%) 75 (79.8) 195 (87.1) 0.01
Tumor localisation (%) 0.001
   colon 89 (94.7) 178 (79.5)
   rectum 5 (5.3) 46 (20.5)
TNM stage (%) 0.68
   I-II   59 (62.8) 135 (60.3)
   III-IV 35 (37.2) 89 (39.7)
Surgery
   timeframe 0.06
      2010-2013 53 (56.4) 151 (67.4)
      2014-2016 41 (43.6) 73 (32.6)
   laparoscopic (%) 72 (76.6) 153 (68.3) 0.14
Hemoglobin (mmol/L)
   at diagnosis (mean, SD) 6.12 ±0.89 6.61 ±0.87 <0.001
Number patients with preop. BT (%) | Hb at diagnosis  <0.001
   yes 30 (31.9)     |  5.67 mmol/L 29 (12.9)  |  5.56 mmol/L
      prior to iron infusion       13              |  5.68 mmol/L NA
      after iron infusion        17              |  5.67 mmol/L NA
   no 64 (68.1)     |  6.32 mmol/L 195 (87.1)  | 6.77 mmol/L
Number patients with postop. BT (%) | number of units transfused
   yes 10 (10.6)     |   28  45 (20.1)    |   91 
   no 84 (89.4)     179 (79.9)  
Number patients with postop. complication (%)  
   yes 24 (25.5)     77 (34.4)  
   no 70 (74.5)    147 (65.6)  
Abbreviations: IV = intravenous iron group, UC = usual care group, BT = blood transfusion, preop. = preoperative, 
postop. = postoperative
Table 1. Patient baseline characteristics of all anemic patients at diagnosis, IV versus UC group
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(mean Hb level at diagnosis of 5.7 mmol/L) blood infusion was administered after iron transfusion. 
Mean Hb level at diagnosis was considerably higher in IV patients who did not receive preopera-
tive blood transfusion (6.3 mmol/L).  
IV versus UC, subgroup 
an overview of the baseline characteristics is presented in table 2. In total, 105 patients were 
included (IV=52, UC=153). In the IV group, 32 and 20 patients received a 1000-2000mg dose of 
iron(III)isomaltoside and iron(III)carboxymaltose, respectively. Both groups had a mean age 
above 70 years (IV=71.3 ±11.6, UC=74.3 ±9.5, p=0.09). In the UC group, more males were included 
as compared to the IV group (60.8% vs 44.2%, p=0.04) and there were more patients with a high 
ASA score (34% versus 19.2%, p=0.04). In the IV group, significantly more patients were operated 
 IV (n=52) UC (n=153) p-value
Characteristics
Age (years mean, SD) 71.3 ± 11.6 74.3 ± 9.5 0.09
Gender (male) (%) 23 (44.2) 93 (60.8) 0.04
ASA-classification 0.045
   I-II 42 (80.8) 101 (66.0)
   III-IV 10 (19.2) 52 (34.0)
Comorbidity (overall) (%) 11 (21.2) 21 (13.7) 0.20
Tumor localisation (%) 0.08
   colon 48 (92.3) 126 (82.4)
   rectum 4 (7.7) 27 (17.6)
TNM stage (%) 0.36
   I-II   34 (65.4) 89 (58.2)
   III-IV 18 (34.6) 64 (41.8)
Surgery
   timeframe 0.31
      2010-2013 31 (59.6) 103 (67.3)
      2014-2016 21 (40.4) 50 (32.7)
   laparoscopic (%) 43 (82.7) 99 (64.7) 0.02
Hemoglobin (mmol/L)
   at diagnosis (mean, SD) 6.3 ± 0.8 6.9 ±0.7 <0.001
Outcome
Hemoglobin (mmol/L)
   increase diagnosis-preop. (mean, SD) 0.65 ±0.74 0.10 ±0.74 <0.001
Abbreviations: IV = intravenous iron group, UC = usual care group, preop. = preoperative
Table 2. Patient baseline characteristics and outcome, IV versus UC subgroup 












laparoscopically (82.7% vs 64.7%, p=0.02). Regarding comorbidity, tumor localisation and tumor 
stage, no significant differences were found. In the IV group, Hb level at diagnosis was significantly 
lower (6.3 mmol/L vs 6.9 mmol/L, p<0.001).  
Patients with intravenous iron treatment showed a significant higher increase of Hb level as 
compared to patients with UC (IV=0.65 mmol/L vs UC=0.10 mmol/L, p<0.001). In identifying char-
acteristics associated with Hb level response after iron infusion, patients receiving one dose 
of iron infusion (1000mg) were classified into high and poor responders. A cut-off value of 0.6 
mmol/L (i.e. median Hb level increase) was used (table 3). In total, 33 patients were included 
(high responder=17, poor responder=16). No significant differences were found for age, gender, 
ASA score, comorbidity, tumor localisation and tumor stage. Regarding iron status at diagnosis, 
Table 3. Patient baseline characteristics high responder (=>0.6 mmol/L Hb increase) versus poor responder (<0.6 
mmol/L Hb increase), receiving 1 dose iron infusion (1000mg)
 IV high responder (n=17) IV poor responder (n=16) p-value
Age (years mean, SD) 69.3 ±13.1 73.6 ±9.0 0.28
Gender (male) (%) 5 (29.4) 5 (31.2) 0.91
ASA-classification 1.0
   I-II 13 (76.5) 13 (81.2)
   III-IV 4 (23.5) 3 (18.8)
Comorbidity (overall) (%) 14 (82.4) 12 (75.0) 0.69
Tumor localisation (%) 0.60
   colon 16 (94.1) 14 (87.5)
   rectum 1 (5.9) 2 (12.5)
TNM stage (%) 0.62
   I-II   12 (70.6) 10 (62.5)
   III-IV 5 (29.4) 6 (37.5)
Iron status at diagnosis
(median; IQR - mean ± SD)
   Hb (mmol/L) 6.0; 1.5  –   6.2 ±0.8 6.8; 1.1   –   6.6 ±0.7
   TSAT (%) 5.3; 4.6  –   7.3 ± 4.6 11; 15     –   16.3 ±14.3
   transferrin (g/L) 2.9; 0.4  –   3.1 ±0.5 2.7; 0.2   –   2.7 ±0.4
   ferritin (μg/L) 12; 27    –   36 ±52 27; 67     –   142 ±360
Abbreviations: IV = intravenous iron group, TSAT = transferrin saturation
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high responders showed more distinct signs of anemia  and iron deficiency as compared to poor 
responders (high versus poor responder, median values: Hb 6.0 mmol/L vs 6.8 mmol/L, transferrin 
saturation (TSAT) 5.3% vs 11%). In addition, increased transferrin (median 2.9 g/L vs 2.7 g/L), and 
decreased ferritin (median 12 μg/L vs 27 μg/L) levels were found in the high responder group.
Association between intravenous iron therapy and postoperative complica-
tions and blood transfusions 
all anemic patients, as presented in table 1, were included in logistic regression analyses. In 
univariable analysis, preoperative intravenous iron administration (OR=0.47, 95%CI 0.23 to 0.99, 
p=0.04) was observed to prevent the administration of postoperative blood transfusion. No 
significant result was found in multivariable analysis (OR=0.54, 95%CI 0.24 to 1.21, p=0.14)(table 
Table 4. Regression analysis on relationship between preoperative intravenous iron and postoperative blood 
transfusion in anemic patients (n=318)
univariable  multivariable  
 OR 95% CI p-value  OR 95% CI p-value
Age (years) 1.02 0.99 - 1.05 0.23 1.02 0.99 - 1.06 0.26
Gender
   female vs. male 0.69 0.38 - 1.26 0.23 0.52 0.27 1.04 0.06
Comorbidity (overall) 1.27 0.54 - 2.99 0.59 1.04 0.39 2.74 0.94
ASA-classification
   III-IV vs. I-II 1.84 1.01 - 3.33 0.045 1.77 0.89 - 3.53 0.11
TNM stage 
   III-IV vs. I-II 0.72 0.39 - 1.33 0.30 0.66 0.34 - 1.28 0.22
Surgery
   laparoscopic versus open 0.51 0.28 - 0.92 0.026 0.55 0.28 - 1.06 0.08
tumor localisation
   rectum vs. colon 1.03 0.47 - 2.26 0.94 1.10 0.98 - 1.24 0.12
timeframe surgery
   2014-2016 vs 2010-2013 0.69 0.37 - 1.30 0.25 0.65 0.32 - 1.32 0.24
Preoperative Hb (0.1 mmol/L increase) 0.48 0.33 - 0.69 <0.001 0.40 0.26 - 0.60 <0.001
Preoperative intravenous iron 0.47 0.23 - 0.99 0.046  0.54 0.24 - 1.21 0.14












Table 5. Regression analysis on relationship between preoperative intravenous iron and postoperative complications 
in anemic patients (n=318)
univariable  multivariable 
 OR 95% CI p-value  OR 95% CI p-value
Age (years) 1.01 0.99 - 1.03 0.51 1.02 0.99 - 1.04 0.30
Gender
   female vs. male 0.43 0.26 - 0.70 0.001 0.36 0.20 - 0.63 <0.001
Comorbidity (overall) 0.67 0.35 - 1.26 0.21 0.48 0.23 - 0.99 0.049
ASA-classification
   III-IV vs. I-II 1.54 0.94 - 2.53 0.09 1.62 0.90 - 2.90 0.11
TNM stage 
   III-IV vs. I-II 0.76 0.47 - 1.25 0.28 0.58 0.34 - 1.00 0.050
Surgery
   laparoscopic versus open 0.33 0.20 - 0.55 <0.001 0.32 0.18 - 0.55 <0.001
tumor localisation
   rectum vs. colon 1.09 0.58 - 2.06 0.79 1.03 0.94 - 1.13 0.54
timeframe surgery
   2014-2016 vs 2010-2013 0.99 0.60 - 1.62 0.96 0.94 0.54 - 1.63 0.81
Preoperative Hb (0.1 mmol/L increase) 1.12 0.85 - 1.47 0.44 1.08 0.79 - 1.48 0.65
Preoperative intravenous iron 0.66 0.38 - 1.12 0.12  0.91 0.50 - 1.68 0.77
4). In both uni- and multivariable analysis, no advantageous effect was found on postoperative 
complications (OR=0.66, 95% CI 0.28 to 1.12, p=0.12 and OR=0.91, 95%CI 0.50 to 1.68, p=0.77, re-
spectively)(table 5).  
DIscussIon
the present study illustrates the efficacy of intravenous iron therapy in the optimisation of pre-
operative hemoglobin level in anemic colorectal cancer patients, as compared to usual care. 
We found that intravenous iron therapy is most effective in patients presenting with more 
severe anemia , and with higher transferrin and lower ferritin levels, markers for an absolute iron 
deficiency, as compared to functional iron deficiency. In present study, the distinct Hb increase 
after iron infusion did not translate into an expected decrease in the percentage of patients with 
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a postoperative blood transfusion. This is most likely due to the confounding effect of preopera-
tive blood transfusions, which  could not be adequately corrected for in this retrospective cohort. 
Our observed perioperative blood transfusion rates are fairly comparable with the perioperative 
blood transfusion rates presented in other large cohort studies22, 23, and our results, therefore, 
could legitimately be generalised. 
Our results add to a growing body of evidence in the literature demonstrating the efficacy of pre-
operative intravenous iron therapy in colorectal cancer patients, and contribute to the ongoing 
debate whether preoperative intravenous iron therapy is improving postoperative outcome. Our 
results are consistent with the results of a prospective randomised trial by Keeler et al., comparing 
the effect of preoperative oral versus intravenous iron in anemic colorectal cancer patients.24 
No overall benefit was seen with intravenous iron in reducing blood transfusions and postop-
erative complications, despite the fact that in the study by Keeler et al. oral iron administration 
represented usual care. However, in addition to the study by Keeler et al., we also identified 
patients characteristics associated with hemoglobin level response after iron infusion. Evidently, 
higher transferrin and lower ferritin levels, markers for absolute iron deficiency, were associated 
with a higher hemoglobin level response after iron infusion. Increased ferritin level, a marker 
for functional iron deficiency, could be the cause of poor hemoglobin level response after iron 
infusion. In this respect, increased uptake and retention of the administered intravenous iron 
within cells of the reticuloendothelial system may lead to a poor availability of administered iron 
for erythropoiesis.8 therefore, these results stress the importance of distinguishing between the 
two types of iron deficiency and emphasize the efficacy of intravenous iron namely in patients with 
absolute iron deficiency. It is noteworthy that in present international guidelines on the treatment 
of anemia  in oncological patients a distinction between type of iron deficiency is already made: 
intravenous iron should be withheld in patients with an active infection and/or if serum ferritin 
exceeds 1000 μg/L 25, 26. Despite this, in current clinical practice, no distinction is made between 
type of iron deficiency. Ongoing and future randomised clinical trials have to establish whether 
the optimisation of preoperative hemoglobin level by preoperative intravenous iron therapy is 
resulting in improved postoperative outcome.11, 13
StrenGth AnD lImItAtIonS  
a key strength of our study is the identification of patient characteristics associated with 
hemoglobin level response after iron infusion in colorectal cancer patients. To our knowledge, this 
is the first study identifying the potential clinical relevance of identifying the type of iron deficiency 
in the treatment of preoperative anemia  not only with oral iron but even with intravenous iron.
The main limitations of our study are three-fold, leading to key recommendations for future 
research.












First, this study represents a retrospective cohort of consecutive patients, involving several 
limitations. The significant differences between the intravenous iron and usual care group (e.g. 
baseline hemoglobin levels and timeframe surgery) could, despite correction in the multivari-
able regressions analyses, potentially indicate selection bias and have significant impact on the 
outcome. Moreover, iron status was not consistently monitored in each patient. The past years, 
great efforts have been made to optimise the results of colorectal cancer surgery. In addition to 
surgical techniques and procedures9, 10, 27, also blood transfusion strategy, as part of patient blood 
management (PBM),  has changed in the course of time. In this regard, the  optimal transfusion 
threshold, dosing, and age of red blood cell (RBC) units have been studied. Presently, a restrictive 
transfusion threshold is recommended for hospitalised adult patients and seems to be safe in 
the oncological setting.28, 29 Moreover, standard-issue RBC units rather than fresh RBC units 
(storage length: <10 days), and, to initiate, one rather than two RBC units are advised.29 although 
we corrected our results for the year of treatment, the combined efforts to optimise colorectal 
cancer care (e.g. centralisation, protocols, laparoscopy) might have contributed differently to the 
results. this emphasises the importance of performing a randomised controlled trial comparing 
usual care (i.e. no therapy or oral iron) with intravenous iron supplementation in colorectal cancer 
patients, in which, importantly, intravenous iron has to be administered as early as possibly, 
preferably at least three weeks prior to surgery for its optimal effect11. 
Second, this study focused specifically on preoperative treatment of anemia . However, investi-
gation and treatment of merely hemoglobin levels appears to be a suboptimal way to indicate 
overall performance and therefore, presently, various multimodal programs are being introduced. 
30, 31 The use of such various modalities could be valuable in preoperative prehabilitation, specifi-
cally in elderly patients (>75 years), in which an increased 1-year mortality of up to 25 percent is 
observed.32, 33 In line with the previous limitation, in present study, various multimodal programs 
may similarly introduce confounding of our results that are not easily corrected for. a randomised 
trial could correct for both continuing pre- as well as postoperative care optimisation.  
The third limitation was that only short-term effects of intravenous iron therapy were studied. In 
this respect, iron is an important growth factor for rapidly proliferating cells, including bacteria 
and tumor cells.8, 34 Several animal experiment studies have shown that exposure to iron to be 
a risk factor for developing colorectal cancer and tumor growth.35, 36 In this regard, intraluminal 
colorectal tumours might be more affected by oral iron administration, while intravenous iron 
with a higher risk of non-transferrin bound serum iron and reactive oxygen species presence 
might also influence systemic tumor growth. Randomised trials on the short-term benefits versus 
the potential long-term hazards of iron therapy in colorectal cancer patients should therefore 
acknowledge the type of anemia  and the associated choice of iron therapy.  
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conclusIon
We were able to show that implementation of intravenous iron therapy leads to optimisation of 
preoperative hemoglobin level. Furthermore, we showed the importance of assessing the type 
of iron deficiency. Iron infusion is most effective in patients with more severe anemia  and with 
higher transferrin and lower ferritin levels, markers for absolute iron deficiency, as compared to 
functional iron deficiency. Following the optimisation of preoperative hemoglobin level, strikingly, 
no significant decrease in the percentage of patients with a  postoperative blood transfusion and 
postoperative complication were observed. however, from present cohort study, due to its retro-
spective nature, we cannot entirely conclude that intravenous iron and the associated hb increase 
does decrease the postoperative blood transfusion and complication rate. Future randomised 
trials are  thus required to not only establish the short-term benefits, but also the potential 
long-term hazards of preoperative intravenous iron therapy in colorectal cancer patients.
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AbstrAct
Introduction: there is an increasing awareness to integrate patient blood management (pBM) 
within routine surgical care in order to improve patient outcome. Although often standard in 
orthopedic and cardiac surgery, limited information about the use and implementation of pBM 
in colorectal cancer surgery is available. this is curious, as preoperative anemia, associated with 
increased morbidity and mortality, is highly prevalent in colorectal cancer patients. the present 
study therefore aimed to assess the current preoperative blood management strategies in the 
Netherlands, and to identify preferences of different physicians in the treatment of preoperative 
anemia in this particular patient group.
Methods: an online electronic survey was developed and sent to all surgeons of the Dutch 
taskforce Coloproctology (177 in total). In addition, for each hospital in which surgery for 
colorectal cancer surgery is performed (75 in total), the survey was sent to one gastroenterolo-
gist and one anesthesiologist. analyses of survey data were performed using descriptive statistics
results: a total of 192 physicians responded to the survey (overall response rate 58.7%). In 73 
hospitals (97.3%) the survey was conducted by at least one physician, and in more detail, in 21 
hospitals (28.0%) the survey was conducted by a surgeon, an anesthesiologist and a gastroen-
terologist. regarding the management of  a mild to moderate preoperative anemia, no clear 
policy was reported in half of the hospitals (49.3%). treatment of  a mild to moderate preop-
erative anemia was initiated by the gastroenterologist, 14.7%; surgeon, 20.0%; colon care nurse, 
5.3%; hematologist, 2.7%; anesthesiologist, 2.7%. In 38.7% of the hospitals, iron parameters were 
measured during screening for colorectal cancer. In addition, in only 13.3% of the hospitals, 
iron parameters were measured by the anesthesiologist during preoperative assessment. the 
most important objective for the treatment of anemia was ‘the prevention of blood transfusions 
because of their association with impaired long-term tumor prognosis’. Furthermore, the severity 
of anemia was considered as the most important factor to treat anemia (98% of all respondents).
conclusion: the present study shows a distinct variability in preoperative blood management 
practices in colorectal cancer care. Strikingly, this variability which was not only seen among, but 
also within Dutch hospitals, was demonstrated by variable responses from gastroenterologists, 
surgeons and anesthesiologists from the same institution. as a result, the present study clearly 
demonstrates the lack of consensus on pBM among gastroenterologists, surgeons and anesthesi-
ologists, resulting in a suboptimal preoperative blood management strategy.













preoperative anemia in colorectal cancer patients is associated with an increased risk of short-term 
mortality and morbidity, and a decrease in long-term tumor survival.1, 2 Iron deficiency is the 
principal cause of preoperative anemia and is reported in almost 50% of preoperative colorectal 
cancer patients.3, 4 transfusion, in earlier days the default therapy to correct this anemia, however, 
is also known to be associated with increased morbidity and mortality, as already demonstrated 
by Busch et al. in 1993.5-9 this has resulted in alternative approaches to treat preoperative anemia, 
which are collectively known as patient blood management (pBM).
pBM refers to ‘the timely application of evidence based medical and surgical concepts designed 
to maintain hemoglobin concentration, optimize hemostasis and minimize blood loss in an effort 
to improve patient outcome’. It has been developed to promote strategies to reduce or avoid the 
need of blood transfusion, and therefore questions blood transfusion as the primary treatment 
strategy of anemia. pBM is a continuous process, initiated early in the preoperative period and 
continued intra- and postoperatively. Importantly, and by definition, PBM requires a multimodal 
and multidisciplinary strategy, and should at least involve surgeons, anesthesiologists, gastroen-
terologists, hematologists and nurses.10
the increasing awareness to integrate pBM within routine surgical care resulted in numerous 
ongoing trials studying the optimal blood management strategy in all types of surgery.11-13 to date, 
studies on the use and implementation of these pBM strategies are mostly limited to orthopedic 
and cardiac surgery.10, 14 Despite the high prevalence of preoperative anemia, associated with 
increased morbidity and mortality, limited information about the use and implementation of 
pBM strategies in colorectal cancer care is available. a review by Munoz et al. represents a clear 
exception to this.15 In this review, the prevalence and consequences of anemia are discussed and 
a pragmatic approach to the treatment of perioperative anemia in colorectal cancer patients is 
presented. 
With the present study, we focused on the preoperative assessment and treatment of anemia in 
colorectal cancer patients and aimed to 1) assess the current preoperative blood management 
strategies in the Netherlands, 2) identify preferences of different physicians (surgeons, anesthe-
siologists and gastroenterologists) in the treatment of preoperative anemia, and 3) evaluate 
physicians’ general knowledge of blood management issues. 
Methods
study design        
to accomplish our objectives, an online electronic survey was developed. the survey included 
three topics: 1) questions on the current preoperative blood management practice in colorectal 
cancer patients (measurement of iron parameters and treatment of preoperative anemia), 2) 
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questions on physicians’ preferences in treatment of preoperative anemia (best treatment of 
preoperative anemia and the goal of treatment) and 3) questions to test physicians’ knowledge 
of blood management issues. the survey questions were made by the research fellow (MJW) 
and two hematologists (MS and JJZ), and were subsequently tested at two sites (Department of 
Surgery reinier de Graaf hospital, and Department of anesthesiology albert Schweitzer hospital). 
the eventual revised questionnaire was sent by e-mail to the eligible participants. the online 
survey tool SurveyMonkey was used to conduct the survey.
study population   
After obtaining the mailing list, the survey was first sent to all surgeons of the Dutch Taskforce 
Coloproctology (Werkgroep Coloprotocologie) in May 2017. Subsequent e-mail reminders were 
sent out in July and September 2017. In addition, for each hospital in which surgery for colorectal 
cancer is performed (75 in total), the survey was sent to one gastroenterologist and one anes-
thesiologist, all involved in colorectal cancer care and usually the head of department. For this 
purpose, the survey was slightly modified to suit the clinical situation of the gastroenterologist 
and anesthesiologist. The first invitation was sent in June 2017 and subsequent e-mail reminders 
were sent out in July and September 2017. the participation period closed in October 2017. 
removal of undeliverable e-mails from the mailing list, as well as retired or relocated surgeons 
resulted in an adjusted study population of 177 surgeons. In addition, the study population 
included 75 gastroenterologists and 75 anesthesiologists. as a result, the total targeted study 
population was 327 physicians.  
statistics
Survey data were extracted into an excel database. Statistical analyses were performed using 




as shown in table 1, a total of 192 physicians responded to the survey (response rate 58.7%), 
including 95 surgeons, 48 anesthesiologists and 49 gastroenterologists. Of 192 respondents, 158 
(82.2%) completed the survey, including 79 surgeons, 38 anesthesiologists and 41 gastroenter-
ologists. In total, in 73 of 75 hospitals (97.3%) one or more physicians responded to the survey. 
In 21 of 75 hospitals (28.0%) the survey was conducted by a surgeon, an anesthesiologist, and a 
gastroenterologist.












Preoperative blood management practice 
regarding the use of red blood cell transfusions and the treatment of severe anemia, respondents 
from all hospitals indicated the perioperative use of a restrictive blood transfusion policy. 
according to the adapted 4-5-6 mmol/L hemoglobin transfusion trigger rule (Dutch transfusion 
guideline), the severity of anemia and the patient-specific cardiopulmonary compensation 
capacity was acknowledged.16
to determine the current preoperative blood management practice per hospital, all respondents 
were first asked to indicate the primarily responsible specialist (gastroenterologist, surgeon, 
hematologist, anesthesiologist, unknown or none) for the management of mild to moderate 
preoperative anemia in colorectal cancer patients. Strikingly, in 33 of 44 hospitals with multiple 
respondents (minimum of two physicians per hospital), these responses differed and were con-
tradictory, and needed reclassification:
1. when per hospital multiple and different responses were given to the question who is primarily 
responsible for the treatment of mild to moderate anemia, the current preoperative blood 
management practice in the hospital was categorized as unclear/ambiguous.  
2. when per hospital multiple and different answers were given to the question whether iron 
parameters are measured during screening for colorectal cancer, the answer of the gastroenter-
ologist was determinant. 
 n % 
Responses per specialism 
   Surgeons (177 invited in total) 95 53.7
   Gastroenterologists (75 invited in total) 49 65.3
   anesthesiologists (75 invited in total) 48 64.0
Responses per hospital (75 in total)
   Surgeon(s) 8 10.7
   Gastroenterologist 4 5.3
   anesthesiologist 9 12.0
   Surgeon(s) + gastroenterologist 14 18.7
   Surgeon(s) + anesthesiologist 12 16.0
   Gastroenterologist + anesthesiologist 5 6.7
   Surgeon(s) + gastroenterologist + anesthesiologist 21 28.0
   No response 2 2.7
Table 1. Characteristics/distribution respondents 
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In twelve hospitals, an ongoing randomized clinical trial (FIt trial) during the survey period studied 
the efficacy of preoperative intravenous iron supplementation in comparison with preoperative 
oral supplementation in anemic patients with colorectal cancer.11 For these twelve hospitals, the 
content of the study protocol of the randomized trial was reflected in all answers regarding pre-
operative blood management practice.
as shown in table 2, iron parameters (iron, ferritin, transferrin, or transferrin saturation) were 
indicated to be measured during screening for colorectal cancer in 38.7% of all hospitals. Of 
these 29 hospitals, complete iron status (iron, ferritin, transferrin, and transferrin saturation) was 
 n %
Iron status measured during screening colorectal cancer
answered by: gastroenterologists and surgeons
   Yes 29 38.7
   No 35 46.7
   Unknown/missing 11 14.7
Treatment of anemia first started by
answered by: gastroenterologists, surgeons and anesthesiologists
   Gastroentrologist 11 14.7
   Surgeon 15 20.0
   Colon care nurse 4 5.3
   hematologist/internist 2 2.7
   anesthesiologist 2 2.7
   Unclear/ambiguous policy 37 49.3
   No treatment 1 1.3
   Unknown/missing 3 4.0
Iron status measured at preoperative assessment anesthesiology
answered by: anesthesiologists
   Yes 8 10.7
   No 37 49.3
   Unknown/missing 30 40.0
Treatment of anemia by anesthesiologists, regardless of previous treatment
answered by: anesthesiologists
   Yes 10 13.3
   No 34 45.3
   Unknown/missing 31 41.3
Table 2. Current practices for preoperative blood management in all centers (n=75), according to respondents 












indicated to be measured in four hospitals.  In a total of 35 hospitals (46.7%), iron parameters 
were not measured during screening. In addition to the measurement of iron parameters during 
screening for colorectal cancer, in ten hospitals (13.3%) iron parameters were measured by the 
anesthesiologist at preoperative assessment, as compared to 37 hospitals (49.3%) in which iron 
parameters were not measured at preoperative assessment. In ten hospitals (13.3%), it was 
indicated that anemia observed at preoperative assessment, regardless of possible previous 
treatment by gastroenterologist or surgeon, was treated by the anesthesiologist, as compared to 
34 hospitals (45.3%) in which this was not the case. 
regarding the treatment of preoperative anemia, respondents from nineteen hospitals (25.3%), 
including the twelve hospitals participating in the ongoing FIt trial, indicated that the surgeons 
or colon care nurses were primarily responsible (table 2). In eleven hospitals (14.7%) the gas-
troenterologist was the first responsible to treat a mild to moderate preoperative anemia. In 
two hospitals each (2.7%), hematologists and anesthesiologists were indicated as primarily 
responsible for treatment, while in one hospital (1.3%) it was indicated that a mild to moderate 
preoperative anemia was not treated. In only four hospitals, the treatment of preoperative anemia 
was reported to be part of a protocol, with the aim of optimizing the preoperative condition of 
a patient. In half of the hospitals (49.3%), no clear policy regarding the treatment of preopera-
tive anemia was reported. In 44 hospitals multiple responses (minimum of two physicians per 
hospital) to the question regarding the treatment of preoperative anemia were given, and in 33 
hospitals (75.0%) these responses differed and were contradictory. 
objectives for treatment of preoperative anemia  
all respondents were asked to prioritize their objectives for treatment of preoperative anemia. 
Results are shown in figure 1. Pooled responses demonstrated that, ‘prevention of blood 
transfusion, because of its association with impaired long-term tumor prognosis’ was ranked first, 
followed by ‘prevention of blood transfusion, because of its short-term side effects’, ‘prevention 
of preoperative anemia, because of its association with impaired long-term tumor prognosis’, 
‘prevention of blood transfusion, because of its high expenses’, and ‘optimization of preoperative 
hemoglobin level for enhanced hemostasis’. This order of preference was similar for the different 
specialisms.  
decision-making in treatment preoperative anemia 
table 3 provides percentages of respondents considering different variables in their decision to 
treat preoperative anemia. Only respondents who had indicated to treat preoperative anemia 
themselves were asked this question. Overall, ‘age of patient’ was considered by 63.3% of all 
respondents, ‘presence iron deficiency’ by 75.5%, ‘presence clinical symptoms of anemia’ by 
85.7%, ‘presence of comorbidities’ by 83.7%, and ‘severity of anemia’ by 98.0%. 
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Figure 2. Respondents opinions on contraindications for intravenous iron
Figure 1. Objective treatment preoperative anemia












In case respondents indicated  that their decision to treat anemia is dependent on the presence 
of iron deficiency, they were asked if the iron formulation (oral or intravenous) would depend on 
the type of iron deficiency (absolute versus functional iron deficiency), and if so, what treatment 
was chosen for an absolute and a functional iron deficiency anemia. Absolute iron deficiency is 
characterized by depleted iron stores (defined by decreased transferrin saturation and increased 
transferrin), while functional iron deficiency is caused by impaired iron homeostasis and is, due 
to increased hepcidin production, characterized by reduced iron uptake and iron mobilization 
from the reticulo-endothelial system (defined by decreased transferrin saturation and increased 
ferritin).  For a small minority of respondents (44.4%) the type of iron deficiency made a difference 
for their treatment. In case of an absolute iron deficiency anemia, intravenous iron was the 
first choice of treatment for 71.4% of these respondents (versus 28.6% oral iron ). In case of a 
functional iron deficiency, the choice of treatment was equally divided (50% oral iron versus 50% 
intravenous iron).
contraindications to intravenous iron therapy 
Figure 2 provides the percentages of respondents identifying different variables as an absolute 










A. Variables considered in decision making treatment preoperative anemia 
   age of patient 16 (76.2) 12 (66.7) 3 (30) 31 (63.3)
   Presence iron deficiency 19 (90.5) 13 (72.2) 5 (50) 37 (75.5)
   presence clinical symptoms anemia 20 (95.2) 14 (77.8) 8 (80) 42 (85.7)
   presence comorbidities 18 (85.7) 15 (83.3) 8 (80) 41 (83.7)
   Severity of anemia 21 (100) 17 (94.4) 10 (100) 48 (98)
B. Type of treatment (oral or intravenous iron) is depending on type of iron deficiency (absolute versus functional iron defi-
ciency)
   Yes 3 (30) 4 (66.7) 1 (50) 8 (44.4)
   No 7 (70) 2 (33.3) 1 (50) 10 (55.6)
C. First choice of treatment in case of an absolute iron deficiency anemia
   Oral iron              0 (0) 2 (50) 0 (0) 2 (28.6)
   Intravenous iron 3 (100) 2 (50) 0 (0) 5 (71.4)
D. First choice of treatment in case of a functional iron deficiency anemia
   Oral iron 1 (33.3) 2 (66.7) 0 (0) 3 (50)
   Intravenous iron 2 (66.7) 1 (33.3) 0 (0) 3 (50) 
Table 3. Decision making in treatment preoperative anemia    
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therapy included ‘anemia not caused by iron deficiency’ for 65.8% of all respondents, ‘iron 
overload’ for 79.7%, ‘hypersensitivity for intravenous iron’ for 86.1%, and ‘bacteremia’ for 15.2%. 
‘renal failure’ was indicated as an absolute contraindication by 15.2% of all respondents. 
Surgeons, gastroenterologists and anesthesiologists (78.5%, 92.1% and 95.1%, respectively) most 
frequently identified hypersensitivity for intravenous iron as absolute contraindication. Gastroen-
terologists and anesthesiologists (4.9% and 13.2%, respectively) least frequently indicated renal 
failure as absolute contraindication, while surgeons least frequently indicated bacteremia in this 
regard (7.6%).
International guidelines on the long-term effects of iron therapy  
Overall, 8.9% of the respondents indicated to believe that the long-term oncological effects of 
intravenous iron therapy are known and already incorporated in the international guidelines 
on the treatment of anemia in cancer patients. 5.7% of the respondents indicated to regard 
intravenous iron as safe, while in contrast 3.2% of respondents believed intravenous iron therapy 
to be associated with impaired long-term tumor prognosis. 22.2% of the respondents indicated 
that the long-term oncological effects of intravenous iron therapy are not studied and therefore 
not included in the international guidelines. a vast majority (69%) indicated to be ignorant on this 
subject. 
dIscussIon
the results of our national survey show a distinct variability in preoperative blood management 
practices in colorectal cancer patients. Strikingly, this variability is not only found among 
hospitals, but also within hospitals, demonstrated by variable responses from gastroenterolo-
gists, surgeons and anesthesiologists from the same institution. as a result, the present study 
clearly demonstrates the lack of consensus on pBM among gastroenterologists, surgeons and 
anesthesiologists, resulting in a suboptimal preoperative blood management strategy. 
extensive research on barriers limiting the translation of pBM into clinical practice has led to 
simplified international recommendations for the implementation of PBM17-21. One of these rec-
ommendations is that each hospital should appoint a key leader for the pBM project management, 
who should have a central role in charge of communication, education, and documentation. this 
should contribute to a more clear division in responsibilities among treating physicians. Our study 
clearly demonstrates that this is not the case for the vast majority of Dutch hospitals. Most gas-
troenterologists, surgeons and anesthesiologists referred to different persons they held primarily 
responsible for the treatment of a mild to moderate preoperative anemia in colorectal cancer 
patients. In the few hospitals practicing preoperative blood management according to protocol, 
the primarily responsible persons were clear for all respondents.  












A second simplified recommendation is derived from the fact that effective correction of anemia 
will depend on the underlying disorder, and states that optimal pBM should involve screening 
for the underlying cause, preferably at the earliest opportunity to allow optimal correction. 
With respect to this recommendation, our study again showed a high variation to which extent 
anemia and underlying causes were investigated and identified.  In only 38.7% of hospitals, 
iron parameters, essential for identifying type of anemia, were indicated to be measured during 
screening for colorectal cancer (by gastroenterologist or surgeon). In addition, in only 13.3% 
of hospitals, iron parameters were measured by the anesthesiologist during preoperative 
assessment. Most strikingly, anemia is, regardless of previous treatment by surgeon or gastroen-
terologists, treated by the anesthesiologist in only a quarter of the hospitals. these results clearly 
indicate that the majority of the Dutch hospitals are failing in the assessment and treatment of 
preoperative anemia.
a third recommendation is that both physicians and nurses need to be trained in pBM clinical 
protocols and transfusion algorithms. according to our results, much progress could be made by 
improving the knowledge of physicians’ on these subjects. For example, in case of a functional iron 
deficiency, the choice of treatment was equally divided between oral and intravenous iron. This 
is a striking and counter-intuitive result, as oral iron is known to be nearly inefficacious in patients 
with a functional iron deficiency. In addition, the results of the acknowledgement of contraindi-
cations to intravenous iron emphasize the knowledge gap of the responding physicians. renal 
failure, the commonest indication for intravenous iron therapy, was considered as an absolute 
contraindication by up to 15.2% of all respondents. Anemia not caused by iron deficiency and iron 
overload, which are clear contraindications to intravenous iron therapy, were indicated as such 
by only 66% and 80% of all respondents respectively. hypersensitivity for intravenous iron is the 
most dangerous contraindication and acute hypersensitivity reactions during infusion are very 
rare but can be life-threatening. a review by rampton et al. provides recommendations about their 
management and prevention.29 Importantly, if intravenous iron is to be given to individuals with 
any of the risk factors for acute hypersensitivity reactions (previous reaction to an iron infusion, 
a fast iron infusion rate, multiple drug allergies, severe atopy, systemic inflammatory diseases), 
an extremely slow infusion rate and meticulous observation is recommended. Finally, and not-
withstanding the observed knowledge gap on pBM issues, possible long-term and potential 
hazardous effects of iron therapy in colorectal cancer patients are still unclear. Therefore, the 
long-term effects of iron therapy are not discussed in regard to the most optimal preoperative 
blood management strategy. Uncertainty on the potential role of iron in tumor progression 
arises from epidemiological and non-clinical studies, showing iron’s role in all aspects of cancer 
development and cancer growth.22-26 Despite the fact that the conditions in these epidemiological 
and non-clinical studies often not reflect the clinical situation in anemic patients and often use 
excessive iron doses iron-replete animals, we believe well-designed clinical studies are required 
to exclude the potential long-term hazardous effect of iron therapy in cancer patients. 
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the increasing awareness to integrate pBM within routine surgical care, has resulted in numerous 
completed and ongoing trials studying the optimal blood management strategy in all types of 
surgery.11, 13, 27, 28 With regard to colorectal cancer, a pragmatic approach to the management of 
perioperative anemia is presented by Munoz et al.15 In this review, the use of pBM is strongly 
advocated to minimize or eliminate the use of allogeneic blood transfusion. regarding the 
treatment of perioperative anemia, the use of oral iron is clearly dissuaded as it is poorly tolerated 
with low adherence based on published evidence, while the use of intravenous iron is strongly 
advised as it is safe and effective, but also frequently avoided due to misinformation and misin-
terpretation concerning the incidence and clinical nature of minor infusion reactions. In addition 
to this review and regarding the efficacy of intravenous iron therapy, a study by Keeler et al.12 
showed that intravenous iron is more effective in increasing hemoglobin level compared to oral 
iron, but did not observe a relevant difference in the administration of red blood cell transfusions. 
however, in this trial the sample size was small and only primary outcomes in terms of increasing 
hemoglobin level and the use of red blood cell transfusions were reported, stressing the need for 
larger trials with a focus on functional performance and quality of life.11 the results of such trials 
should provide more evidence surrounding the effectiveness of the management of preoperative 
anemia, and should contribute to successful implementation of PBM protocols, specifically in 
colorectal cancer patients.  
strengths And lIMItAtIons 
the key strength of our study is the availability of responses from gastroenterologists, surgeons 
and anesthesiologists. This enables comparison between different medical disciplines within 
and between hospitals. Our data sets allows assessing the knowledge of the different types of 
physicians and assessing the consensus in the management of preoperative anemia.  In addition, 
in all hospitals except two, at least one physician responded to the survey. While the availability of 
responses from gastroenterologists, surgeons and anesthesiologists is a key strength of our study, 
it also appeared to be a limitation. Due to the high variety in responses, it was extremely difficult 
to determine the actual preoperative blood management strategy per hospital. an additional 
limitation of our study is that it is a national survey, hampering generalization of our results to an 
international setting. however, the Netherlands are known to be a pioneer in the implementa-
tion of pBM, using pBM strategies for more than two decades, especially for major orthopedic 
surgery.10 therefore in other countries, physicians’ knowledge of blood management issues and 
implementation of pBM in colorectal cancer care will presumably not be superior to the Dutch 
setting.
conclusIon
the present study shows a distinct variability in preoperative blood management practices in 
colorectal cancer care. Strikingly, this variability which was not only seen among, but also within 












Dutch hospitals, was demonstrated by variable responses from gastroenterologists, surgeons 
and anesthesiologists from the same institution. as a result, the present study clearly demon-
strates the lack of consensus on pBM among gastroenterologists, surgeons and anesthesiolo-
gists, resulting in a suboptimal preoperative blood management strategy. For a more effective 
and uniform implementation of pBM, much progress could be made on education as the present 
study clearly demonstrates a significant information deficit among physicians dealing with PBM 
issues. In addition, results of clinical trials providing evidence surrounding the effectiveness of 
treatment of preoperative anemia should contribute to more evidence-based guidelines. Finally, 
appointing key leaders for pBM project management should contribute to improved commu-
nication and cooperation, resulting in a more clear division in responsibilities among treating 
physicians. 
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AbstrAct
In colorectal cancer patients, iron therapy, and especially intravenous iron therapy, is increas-
ingly used to treat anemia and reduce the use of blood transfusions. however, iron has also been 
shown to be an essential nutrient for rapidly proliferating tissues and cells. In this respect, anemia 
of inflammation, characterized by limited duodenal iron uptake and sequestration of iron into the 
reticuloendothelial system, might be regarded as a potentially effective defense strategy of the 
human body against tumor growth. We therefore hypothesize that iron therapy, by supporting 
colorectal tumor growth and increasing the metastatic potential, may worsen tumor prognosis 
in colorectal cancer patients. this hypothesis is particularly supported for colorectal cancer by 
laboratory, epidemiological and animal studies, demonstrating the role of iron in all aspects of 
tumor development growth. Compared to non-malignant colon cells, tumor cells differ in the 
levels and activity of many iron import and export proteins, resulting in an increase in intracel-
lular iron level and enhanced proliferation. In addition, it is demonstrated that iron is able to 
amplify Wnt signaling in tumors with apc mutation, a critical mutation in the development of 
colorectal cancer. If our hypothesis is to be confirmed, current practice of iron administration, as 
treatment for anemia and as replacement of blood transfusions, can be hazardous and should be 
completely reconsidered.













Colorectal cancer is the third most commonly diagnosed cancer in men and the second in women 
worldwide, accounting for more than 1.4 million new cases and 694 000 associated deaths 
worldwide.1 Anemia (hemoglobin <12.0 g/dL) is the most frequent hematological manifestation in 
patients with cancer, occurring in >40% of the cases. In colorectal cancer, anemia is even reported 
in around 60% of the cases.2 This anemia is most often associated with iron deficiency,3 but more 
importantly also with impaired disease-free and overall survival in cancer patients.4, 5
as both blood transfusions and erythropoiesis-stimulating agents (eSas) are, similar to anemia, 
independently associated with an increased risk of colorectal cancer recurrence and increased 
mortality,6-9 the use of iron to reverse anemia has gained more attention. In this regard, while 
oral iron does correct anemia, it also causes constipation, and is largely ineffective in patients 
with anemia of inflammation, characterized by reduced duodenal iron uptake and iron mobiliza-
tion from the reticulo-endothelial system. In comparison with oral iron, intravenous iron does 
not have these disadvantages and is therefore more and more preferred.10 In colorectal cancer 
patients, several cohort studies have shown that intravenous iron therapy indeed optimizes pre-
operative hemoglobin level. a net reduction of blood transfusions by intravenous iron, however, 
is not conclusively shown as of yet. 11-14
In contrast to the short-term effect of iron therapy to increase the hemoglobin level, strikingly, 
possible long-term effects in colorectal cancer patients, such as survival, are so far hardly studied. 
These long-term effects are of special interest since anemia of inflammation is believed to be a 
potentially defense strategy of the human body to limit the growth of tumor cells.15 In this respect, 
the results of laboratory, epidemiological and animal studies indeed have shown iron’s role 
in all aspects of cancer development and cancer growth.11, 16-21 Finally, corroborating evidence 
implicates that especially gastrointestinal cancer cells, likely by their original iron-absorbing 
nature, have an altered iron homeostasis.22
the hypothesIs 
We hypothesize that iron therapy may worsen colorectal tumor prognosis by supporting colorectal 
tumor growth and increasing the metastatic potential. although no direct evidence is available to 
date, accumulative data from experimental studies are in favor of this hypothesis. In this respect, 
importantly, iron therapy is increasingly used with the aim of optimizing hemoglobin level and 
reducing the need for blood transfusions. Therefore, this hypothesis is in striking contrast with 
current practice in patient blood management. We evaluated the current evidence supporting 
this hypothesis in the following part. 
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evAluAtIon of the hypothesIs  
Iron is an essential nutrient participating in numerous biological and cellular processes such 
as hemoglobin-mediated oxygen transport, DNa synthesis and cell proliferation and growth. 
as mammals do not possess any regulated mechanisms for iron excretion from the body, iron 
metabolism is maintained by the tight control of dietary iron absorption in the duodenum. In-
tracellular iron transport is mainly controlled by three iron transport proteins: 1. divalent metal 
transporter 1 (DMt1), facilitating the transport of dietary iron across the apical membrane of 
enterocytes 2. ferroportin, facilitating the export across the basolateral membrane into the 
bloodstream, and 3. transferrin receptor 1 (tfr1), facilitating the import across the basolateral 
membrane into the cell. Systemically, iron homeostasis is regulated by hepcidin, which is 
produced by hepatocytes and inhibits the release of iron from enterocytes and macrophages into 
the circulation by inducing the internalization and subsequent degradation of ferroportin.23, 24 the 
level of hepcidin is controlled by many factors including iron stores, hypoxia, anemia and erythro-
poiesis.25, 26 Whereas iron deficiency, enhanced red blood cell production, and hypoxia decrease 
hepcidin expression to accelerate iron absorption, iron overload and inflammatory stimuli like IL-6 
induce increased hepcidin expression. the latter is the cause of a hepcidin-mediated decrease in 
iron uptake and utilization, so called anemia of chronic disease or anemia of inflammation.
Abovementioned background information on the normal regulation of iron metabolism is 
essential to put the modifications in intracellular iron regulation in colorectal cancer cells in 
perspective. In distinct favor of our hypothesis, many transport proteins that were originally 
studied for their roles in normal iron metabolism have now been shown to contribute to malignant 
tumor growth. Compared to non-malignant colon cells, iron import proteins, such as DMt1 and 
TfR1, are upregulated, while ferroportin, the only known iron export protein, is downregulated 
in colon tumor cells, subverting the normal homeostatic control into a chronic iron acquisition 
state enabling enhanced proliferation.27-29 More in detail, the presence of the key intestinal tumor 
suppressor apc seems to play a pivotal role. the apc gene is the most commonly mutated tumor 
suppressor gene in sporadic colorectal cancer,30 and it is shown that especially Apc-deficient (i.e. 
mutant Apc) cells appear critically dependent iron for efficient tumor growth. In Apc-deficient 
cells, raising the levels of iron induces the expression of tfr1 and DMt1, resulting in increased 
iron content in the cells and increased proliferation, while removal of iron drives apoptosis of 
Apc-deficient cells. This is the exact opposite to what is observed in colorectal cancer cells with 
wildtype apc.17, 31 In addition, it is demonstrated that, in mouse models, the growth rate of tumor 
xenografts is increased by high levels of dietary iron.32, 33
Finally, in studying the proliferative effect of iron in colorectal tumors, a clear link between iron 
and Wnt signaling was found30, 34, 35. Wnt signaling plays a critical role in regulating homeostasis 
and self-renewal of tissues, and in the intestinal epithelium it promotes proliferation and differen-
tiation of stem cells in the intestinal crypts. aberrant Wnt signaling is closely related to a mutation 












in Apc, and is an important hallmark for colorectal cancer development. Importantly, and 
supporting our hypothesis, it is demonstrated that iron, in the background of an Apc mutation, 
is able to amplify Wnt signaling, and with it induction of cell growth.36 therefore, in the presence 
of an Apc mutation, iron will affect Wnt signaling and with it an increase in the tumorigenic and 
metastatic potential.37 
consequences of the hypothesIs And dIscussIon 
Substantial evidence suggests that iron promotes colorectal tumor growth and potentially 
increases the metastatic potential of colorectal tumor cells. Therefore, the legitimate question 
arises as to whether the use of iron therapy, either orally or intravenously, is a safe and optimal 
treatment strategy in anemic colorectal cancer patients. 
We hypothesize that iron in general (i.e. both oral and intravenous) may worsen colorectal tumor 
prognosis, but the different routes of administration should be considered. In colorectal cancer 
patients, oral iron often is poorly absorbed. As a consequence, only a fraction of the dietary (i.e. 
orally administered) iron will reach the sites of erythropoiesis and a significant part will reach 
the site of the primary tumor. At the site of the primary tumor, the oral iron will be able to affect 
Wnt signaling and contribute to enhanced tumor growth and increased metastatic potential. 
However, and in contrast with intravenous iron, the effect of oral iron will be limited to the primary 
tumor. In this respect, intravenous iron might have more influence if metastases are present.
In addition to the different routes of administration, we hypothesize that the assessment of type 
of iron deficiency anemia might be important in studying the long-term effect of iron therapy. 
Chronic blood loss, as can be envisioned by bleeding from gastrointestinal tumors, in this respect 
causes absolute iron deficiency (AID), characterized by depleted iron stores. Functional iron 
deficiency (FID), in contrast, is caused by impaired iron homeostasis and is, due to increased 
hepcidin production, characterized by reduced iron uptake from the duodenum and iron mobi-
lization from the reticulo-endothelial system. FID resulting in anemia is also known as anemia of 
inflammation or anemia of chronic disease. Despite definite evidence, FID could be regarded as a 
potentially effective defense strategy to inhibit growth of pathogens and tumor cells.15 as, in the 
event of FID, a large fraction of oral iron will, due to poor absorption in the duodenum, reach the 
site of the primary tumor, we hypothesize that iron supplementation will be more hazardous in 
patients with FID, as compared to patients with aID. 
In assessing the effect of iron therapy on tumor growth and tumor prognosis, the dose-response 
relationship will be particularly important. a single dose of intravenous iron normally contains 
1000 mg, which is, as compared to a daily iron uptake of 1-2 mg, an extremely high amount of 
extra iron. Total body iron is 3-4 g, and this quantity is tightly regulated. However, the body has 
no mechanism to excrete excess iron and only less than 0.1% of total iron is lost on average daily, 
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mostly through urine, sweat and feces. therefore, and despite the relatively large amount of 3-4 
g of total body iron, we hypothesize that a single dose of intravenous iron or continuous sup-
plementation of oral iron (i.e. normally 400-500 mg daily) could already affect tumor growth and 
therefore be harmful, especially in iron-dependent tumors. 
Testing our hypothesis will be challenging. In a retrospective cohort study significant differences 
between an iron-treatment and non-iron treatment group (e.g. baseline hemoglobin levels 
and use of blood transfusions) could, despite possible correction by multivariable regressions 
analyses, potentially indicate selection bias and have significant impact on the outcome. 
Therefore, to show the validity of our hypothesis, the clinical long-term effect of iron therapy 
should be studied in a prospective trial. In such a trial, anemic patients should be randomized 
into an iron-treatment and a non-treatment group. In addition, clinical outcome should be 
correlated with both tumor (e.g. expression levels of iron transporters, apc status, tumor stage 
and molecular subtype38) and patient characteristics. Only such a set up will allow identifica-
tion of iron-dependent tumor growth and potential high-risk patients. Apart from studying the 
clinical long-term consequences of iron therapy, assessing the optimal management of anemia 
in colorectal cancer patients is more challenging. For this purpose, the detrimental long-term 
effects of iron treatment must be compared with those of not only anemia, but also alternatives 
to treat anemia like ESAs and more important blood transfusions. The problem here is that a 
head-to-head comparison of blood transfusion and iron therapy seems almost impossible. the 
indications for both therapies are namely clearly different. Iron therapy is indicated in patients 
with a mild to moderate anemia, while blood transfusion are only administered in case of severe 
anemia. as a useful alternative for clinically assessing the optimal management of anemia, animal 
experiments could be considered. In an ortho- or heterotopic rodent model, the effect on tumor 
growth of both anemia, blood transfusion and iron therapy (both oral and intravenous) could be 
accurately assessed and compared. 
In conducting a prospective trial randomizing anemic patients in an iron-treatment and a non-
treatment group, ethical issues should be considered. anemia itself is considered as a major 
risk factor for impaired disease-free and overall survival in cancer patients,4, 5 and therefore the 
inclusion of a non-treatment (i.e. anemic) group could be considered unethical. to challenge 
this ethical issue, the proposed and abovementioned animal experiments studying the effect on 
tumor growth of both anemia, blood transfusion and iron therapy will play a pivotal role. these 
animal experiments should precede a clinical trial studying the long-term effects of iron therapy. 
If anemia is proven to be significantly associated with highest tumor growth, the clinical study 
design should be reconsidered. this could, for example, include the administration of iron therapy 
in all anemic patients, subdivided into patients with iron-dependent and non-iron dependent 
colorectal tumor phenotypes. assessment of the iron-dependency of the tumor could be done by 
identification of gene and protein expression levels of iron transporters. If iron therapy is proven 












to be significantly associated with impaired tumor prognosis in the iron-dependent group, this 
probably indicates the hazardous effect of iron therapy.
Interestingly, corroborating data about the possible detrimental effects of iron can be deduced 
from a report by harlaar et al,39 comparing the long-term effects of autologous and allogeneic 
blood transfusions in colorectal cancer patients. they unexpectedly showed that patients with 
autologous blood transfusion, with an a priori lower probability to dysregulate the immune 
system of the recipient, showed an inferior long-term survival as compared to patients transfused 
with allogeneic blood. Interestingly, the patients with autologous blood transfusion addition-
ally received preoperative oral iron therapy to maintain normal hemoglobin levels after blood 
donation.
In conclusion, if iron therapy indeed can be shown to worsen colorectal tumor prognosis, this 
should change current management of anemia in colorectal cancer patients. Focus will be shifted, 
and minimization of the use of blood transfusions will no longer be the main objective. Paradigms 
will be shifted in patient blood management, which will bear major changes in oncological care 
as a whole.  
MichaelWilson.indb   91 13-11-2018   14:37:48
92  |   Chapter 6
references
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in 
GLOBOCaN 2012. Int J Cancer 2015; 136(5):e359-86.
2. Ludwig h, Van Belle S, Barrett-Lee p, et al. the european Cancer anemiaSurvey (eCaS): a large, multinational, prospective 
survey defining the prevalence, incidence, and treatment of anemiain cancer patients. Eur J Cancer 2004; 40(15):2293-306.
3. Wilson MJ, Dekker JWT, Harlaar JJ, et al. The role of preoperative iron deficiency in colorectal cancer patients: prevalence and 
treatment. Int J Colorectal Dis 2017.
4. Caro JJ, Salas M, Ward a, et al. anemia as an independent prognostic factor for survival in patients with cancer: a systemic, 
quantitative review. Cancer 2001; 91(12):2214-21.
5. Wilson MJ, van haaren M, harlaar JJ, et al. Long-term prognostic value of preoperative anemia in patients with colorectal 
cancer: a systematic review and meta-analysis. Surg Oncol 2017; 26(1):96-104.
6. acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients 
undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 2012; 256(2):235-44.
7. amato a, pescatori M. perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 
2006(1):CD005033.
8. Bohlius J, Schmidlin K, Brillant C, et al. recombinant human erythropoiesis-stimulating agents and mortality in patients with 
cancer: a meta-analysis of randomised trials. Lancet 2009; 373(9674):1532-42.
9. pascual M, Bohle B, Alonso S, et al. Preoperative administration of erythropoietin stimulates tumor recurrence after 
surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism. J Surg Res 2013; 
183(1):270-7.
10. Borstlap WA, Buskens CJ, Tytgat KM, et al. Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion 
with oral iron supplementation in the treatment of preoperative anemiain colorectal cancer patients. BMC Surg 2015; 15:78.
11. Borstlap W, Stellingwerf Me, Moolla Z, et al. Iron therapy for the treatment of preoperative anemiain patients with colorectal 
carcinoma: a systematic review. Colorectal Dis 2015.
12. Calleja JL, Delgado S, del Val a, et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon 
cancer and anemia. Int J Colorectal Dis 2016; 31(3):543-51.
13. Keeler BD, Simpson JA, Ng O, et al. Randomized clinical trial of preoperative oral versus intravenous iron in anemic patients 
with colorectal cancer. Br J Surg 2017.
14. Laso-Morales M, Jerico C, Gomez-Ramirez S, et al. Preoperative management of colorectal cancer-induced iron deficiency 
anemia in clinical practice: data from a large observational cohort. Transfusion 2017.
15. Weiss G, Goodnough Lt. anemia of chronic disease. N Engl J Med 2005; 352(10):1011-23.
16. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk--a systematic review and meta-analysis of the epidemiological 
evidence. Cancer Epidemiol Biomarkers Prev 2014; 23(1):12-31.
17. Ilsley JN, Belinsky GS, Guda K, et al. Dietary iron promotes azoxymethane-induced colon tumors in mice. Nutr Cancer 2004; 
49(2):162-9.
18. Stevens RG, Jones DY, Micozzi MS, et al. Body iron stores and the risk of cancer. N Engl J Med 1988; 319(16):1047-52.
19. torti SV, torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013; 13(5):342-55.
20. Xue X, Shah YM. Intestinal iron homeostasis and colon tumorigenesis. Nutrients 2013; 5(7):2333-51.
21. Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell 
2015; 6(2):88-100.
22. hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-74.
23. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its inter-
nalization. Science 2004; 306(5704):2090-3.












24. Wu XN, Su D, Wang L, et al. roles of the hepcidin-ferroportin axis and iron in cancer. Eur J Cancer Prev 2014; 23(2):122-33.
25. Ganz t, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008; 112(10):4292-7.
26. Nicolas G, Chauvet C, Viatte L, et al. the gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, 
and inflammation. J Clin Invest 2002; 110(7):1037-44.
27. Brookes MJ, hughes S, turner Fe, et al. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 2006; 
55(10):1449-60.
28. hamara K, Bielecka-Kowalska A, Przybylowska-Sygut K, et al. Alterations in expression profile of iron-related genes in 
colorectal cancer. Mol Biol Rep 2013; 40(10):5573-85.
29. Ward DG, Roberts K, Brookes MJ, et al. Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 2008; 
14(9):1339-45.
30. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103(2):311-20.
31. radulescu S, Brookes MJ, Salgueiro P, et al. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep 
2012; 2(2):270-82.
32. hann HW, Stahlhut MW, Blumberg BS. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. 
Cancer Res 1988; 48(15):4168-70.
33. hann HW, Stahlhut MW, Menduke H. Iron enhances tumor growth. Observation on spontaneous mammary tumors in mice. 
Cancer 1991; 68(11):2407-10.
34. Klaus a, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat rev Cancer 2008; 8(5):387-98.
35. reya t, Clevers h. Wnt signalling in stem cells and cancer. Nature 2005; 434(7035):843-50.
36. Brookes MJ, Boult J, roberts K, et al. a role for iron in Wnt signalling. Oncogene 2008; 27(7):966-75.
37. Vermeulen L, De Sousa EMF, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the 
microenvironment. Nat Cell Biol 2010; 12(5):468-76.
38. Guinney J, Dienstmann r, Wang X, et al. the consensus molecular subtypes of colorectal cancer. Nat Med 2015.
39. harlaar JJ, Gosselink MP, Hop WC, et al. Blood transfusions and prognosis in colorectal cancer: long-term results of a 
randomized controlled trial. Ann Surg 2012; 256(5):681-6; discussion 686-7.
MichaelWilson.indb   93 13-11-2018   14:37:48
MichaelWilson.indb   94 13-11-2018   14:37:49
M.J. Wilson, J.W.T. Dekker, S. Buettner, J.J. Harlaar, J. Jeekel, M. 
Schipperus,  J.J. Zwaginga
Chapter 7 // The effect of intra-
venous iron therapy on long-term 
survival in anemic colorectal 
cancer patients: results from a 
matched cohort study
MichaelWilson.indb   95 13-11-2018   14:37:51
96  |   Chapter 7
AbstrAct
Introduction: Intravenous iron therapy has been shown to be advantageous in treating anemia 
and reducing the need for blood transfusions. Iron treatment, however, may also be hazardous by 
supporting cancer growth. Present clinical study explores, for the first time, the effect of preopera-
tive intravenous iron therapy on tumor prognosis in anemiccolorectal cancer patients.   
Methods: a retrospective cohort study was performed on consecutive patients who underwent 
surgery for colorectal cancer between 2010-2016 in a single teaching hospital. the primary 
outcomes were 5-year overall survival (OS) and disease-free survival (DFS). Survival estimates 
were calculated using the Kaplan-Meier method and patients were matched based on propensity 
score.
results: 320 (41.0%) of all eligible patients were anaemic, of whom 102 patients received pre-
operative intravenous iron treatment (31.9%). After propensity score matching 83 patients were 
included in both intravenous and non-intravenous iron group. the estimated 1-, 3-, and 5-year OS 
(91.6%, 73.1%, 64.3%, respectively) and DFS (94.5%, 86.7%, 83.4%, respectively) in the intravenous 
iron group were comparable with the non-intravenous iron group (p=0.456 and p=0.240, respec-
tively). In comparing patients with an event (death or recurrence) and no event in the intravenous 
iron group, a distinct trend was found for decreased transferrin in the event group (median 2.53g/L 
vs 2.83g/L, p=0.052).
conclusion: the present study illustrates that a dose of 1000-2000mg preoperative intravenous 
iron therapy does not have a profound effect on long-term overall and disease-free survival in 
anemiccolorectal cancer patients. Future randomised trials with sufficient power are required to 
draw definite conclusions on the safety of intravenous iron therapy.













anemia is a frequent complication in malignancies and is present in up to 30% of all colorectal 
cancer patients.1, 2 preoperative anemia is reported to be an independent prognostic factor for 
impaired short- and long-term outcome.3-5 although a causal relationship has not yet been dem-
onstrated, the reported association has led clinicians to aim for correcting preoperative anemia 
with the aim of improving survival of colorectal cancer patients. treatment options for anemia 
include the use of erythropoiesis-stimulating agents (eSas), blood transfusion and iron therapy. as 
both blood transfusions and eSas are, similar to preoperative anemia, independently associated 
with an increased risk of cancer recurrence and increased mortality6-10, the use of iron therapy is 
gaining more attention.11
Iron deficiency (ID) is the most common cause of preoperative anemia in colorectal cancer 
patients.2, 12 This implicates that optimising preoperative hemoglobinlevel often can be accom-
plished by preoperative iron supplementation. While oral iron has been shown to correct anemia, 
it is also known to be absorbed slowly, to cause constipation, and to be largely ineffective in 
patients with anemia of chronic disease.13 therefore, the use of intravenous iron has received more 
consideration. In this regard, several cohort studies have shown that intravenous iron therapy in 
colorectal cancer patients indeed optimises preoperative hemoglobinlevel and reduces the use 
of red blood cell transfusions.14-16 
The effect of intravenous iron, however, on immediate postoperative complication rate has not 
been elucidated. Also possible long-term effects in colorectal cancer patients are unknown. These 
long-term effects are of special interest while laboratory, epidemiological and animal studies 
have shown iron’s role in all aspects of cancer development and cancer growth.17-23 Corroborating 
evidence moreover implicates changes in the uptake and management of iron as crucial feature 
of growth of gastrointestinal cancer cells, and suggests that altered iron metabolism is a key 
metabolic hallmark of gastrointestinal cancer. 24
Considering this established hazardous role of iron in cancer development and especially cancer 
growth, the important question arises as to whether intravenous iron therapy is negatively 
affecting tumor prognosis in colorectal cancer patients, independently of the presence of anemia 
and the use of blood transfusions. The present clinical study explores, for the first time, this 
long-term effect of intravenous iron therapy on tumor prognosis in colorectal cancer patients.   
Methods
Patient selection
In this retrospective analysis, all patients undergoing resection for colorectal cancer between 1 
January 2010 and 1 July 2016 at the Department of Surgery of reinier de Graaf, a teaching hospital 
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in the Netherlands, were identified.  Consecutive patients diagnosed with anemia (men hb <8.0 
mmol/L, 12.9 g/dL; women hb <7.5 mmol/L, 12.0 g/dL) were eligible for inclusion. Patients who 
had surgery in an emergency setting were excluded. In our institution, over the course of the 
last 5 years, preoperative intravenous iron therapy was administered more frequently in ane-
micpatients. as treatment of anemia was mostly depending on the clinical assessment, and on 
the knowledge of patient blood management of each physician,  not all anemicpatiens received 
intravenous iron therapy. None of the patients awaiting surgery in our center did receive preop-
erative oral iron therapy or erythropoiese-stimulating agents (eSas).
data collection   
all data concerning preoperative blood management and long-term survival, including the 
use of preoperative iron therapy and blood transfusion, hb values and iron status (i.e. ferritin, 
transferrin, transferrin saturation) at diagnosis of colorectal cancer, and overall survival (OS) and 
disease-free survival (DFS) were manually obtained from medical records. In this respect, the pre-
operative period was defined as the time from diagnosis to surgery. Administration of intravenous 
iron therapy was defined by a dose of 1000-2000mg iron(III)carboxymaltose (Ferinject) or iron(III)
isomaltoside (Monofer). None of the patients awaiting surgery in our center did receive preop-
erative oral iron therapy or erythropoiese-stimulating agents (eSas). Clinical and pathological 
data, including age, gender, ASA-classification, overall comorbidities (i.e. cardiologic, vascular, 
diabetes, pulmonic, neurologic, thrombotic, urologic, musculoskeletal, infectious, malignancy, 
endocrine) tumor type, pathological tumor stage and neoadjuvant treatment were collected by 
the Dutch Surgical Colorectal Audit (DSCA), a disease-specific national audit. This audit collects 
information on patient, tumor, treatment, and 30-day and in-hospital outcome characteristics of 
all patients undergoing a resection for primary colorectal carcinoma in the Netherlands. the data 
set is cross-checked on a yearly basis with data from the Netherlands Cancer registry.25
statistical Analysis 
Categorical variables were described as whole numbers and percentages while continuous 
variables were reported as medians with interquartile (IQr) range. Percentages for each variable 
were calculated based on available data, excluding missing values. Univariable comparison, 
comparing patients with preoperative intravenous iron therapy with patients with no intravenous 
iron therapy, was performed using the Pearson chi-square test for categorical variables and using 
the Mann-Whitney U-test for continuous variables. the primary outcomes of the study were 
5-year DFS and OS. DFS was calculated from the date of surgery to the first date of radiological 
or pathological evidence of recurrence or metastases or the date of last follow-up, as applicable. 
OS was calculated as the time from the date of surgery to the date of death or date of last 
available follow-up. Survival estimates were calculated using the Kaplan-Meier method. patients 
diagnosed with metastatic disease (i.e. aJCC tNM stage 4) and with non-curative intent treatment 












were excluded in calculating DFS estimate. In addition, in patients with recurrent disease time to 
recurrence was compared between the intravenous iron and non-intravenous iron group using 
the Mann-Whitney U-test. In order to correct for the baseline differences between the treatment 
groups, patients were matched based on propensity score, with a caliper of 0.10. Variables 
matched for were tumor location, hb level at diagnosis, treatment approach and resection type 
(all p<0.1). Finally, in all patients in the intravenous iron group and with a minimum follow up of 2.5 
years, iron status was studied as a predictive factor for long-term survival using the Mann-Whitney 
U-test. all analyses were performed using SpSS 22.0 (IBM, New York) and the MatchIt package for 
r 3.0.3 (https://cran.r-project.org/). All tests were 2-sided and p<0.05 defined statistical signifi-
cance.
ethical approval for this study was provided by the ethical Committee MetC Zuidwest holland. 
Our institution, a teaching hospital, is making use of opt-out consent.  each included patients had 
given consent by not declining to give consent. 
results
In total, 863 patients underwent surgery for colorectal cancer, of whom 82 patients were excluded 
because of surgery in an emergency setting. a total of 320 patients (41.0%) were anemicat 
diagnosis, of whom 102 patients received preoperative intravenous iron treatment (31.9%). No 
patient received oral iron or eSas in the preoperative period. Baseline characteristics are shown 
in table 1. Median age at presentation was 74 years (66-80) and the majority of patients was 
male (54.4%). Most patients were operated laparoscopically (70.9%) and the most frequently 
performed resection was right colectomy (56.6%), followed by sigmoid resection/low anterior 
resection/abdominoperineal resection (31.9%), left colectomy (9.7%) and other (i.e. panproc-
tolectomy, subtotal colectomy) (1.9%). 125 (39.1%) patients were classified as TNM stage 3 or 4, 
and 24 patients (7.5%) presented with distant metastases (i.e. tNM 4).
Baseline characteristics of the intravenous iron (IV) versus the non-intravenous iron (no IV) group 
are presented in table 2. Both groups had a median age above 70 years (IV=75.0 (67-80), no IV=73.5 
(66-80); p=0.44). In the IV iron group, the majority of patients presented with a tumor in the colon 
(91.2% vs 80.3%, p=0.01) and was more often operated laparoscopically (77.5% vs 67.9%, p=0.08). 
In addition, right colectomy was most performed in IV iron patients (67.6% vs 51.4%, p=0.004). hb 
level (mmol/L) at diagnosis was significantly lower in the IV iron group (6.0 (5.5-7.0) vs 6.7 (6.1-7.3), 
p<0.001). regarding gender, ASA classification, TNM stage and administration of preoperative 
blood transfusion, no significant differences were observed. Median follow-up was 47 months.
To correct for the baseline differences between the treatments groups, propensity score matching 
was executed for tumor location, hb level at diagnosis, treatment approach and resection type, 
and led to 83 patients in each group. With this, no significant differences were observed in the 
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Table 1. Baseline characteristics of all anemic patients (n = 320)
Characteristic n (%) / median (IQR)
Male gender 174 (54.4)















    (extended) right colectomy/transversum 181 (56.6)
    (extended) left colectomy 31 (9.7)
    Sigmoid resection/low anterior resection/abdominoperineal resection 102 (31.9)




Distant metastases 24 (7.5)
preoperative blood transfusion 50 (15.6)
preoperative intravenous iron 102 (31.9)
baseline characteristics of both groups (tumor location p=0.48, hb level p=0.89, treatment 
approach p=0.72, resection type p=0.76)(table 3).












Table 2. Baseline characteristics, IV versus no IV 
Characteristic, n (%) / median (IQR) No IV Iron (n = 218) IV Iron (n = 102) p value
Male gender 120 (55.0) 54 (52.9) 0.73
age, years 73.5 (66.0-80.0) 75.0 (67.0-80.0) 0.44
tumor location 0.01
Colon 175 (80.3) 93 (91.2)
rectum 43 (19.7) 9 (8.8)
aSa 0.96
1-2 148 (67.9) 69 (67.6)
3-4 70 (32.1) 33 (32.4)
treatment approach 0.08
Open 70 (32.1) 23 (22.5)
Laparoscopic 148 (67.9) 79 (77.5)
resection 0.004
    (extended) right colectomy/transversum 112 (51.4) 69 (67.6)
    (extended) left colectomy 23 (10.6) 8 (7.8)
    Sigmoid resection/low anterior resection/abdominoperineal resection 81 (37.2) 21 (20.6)
    Other 2 (0.9) 4 (3.9)
aJCC tNM stage
1-2 132 (60.6) 63 (61.8)
3-4 86 (39.4) 39 (38.2) 0.78
Distant metastases (tNM 4) 18 (8.3) 6 (5.9) 0.45
Dose intravenous iron
   1000mg - 68 (66.7)
   2000mg - 34 (33.3)
preoperative blood transfusion 34 (15.7) 16 (15.7) 0.99
hb at diagnosis (mmol/L) 6.7 (6.1-7.3) 6.0 (5.5-7.0) <0.001
recurrent disease (excluding M+ patients) 38 (18.9) 11 (11.3)
   Local               0 (0)                1 (1.0)
   Distant               33 (16.4)                10 (10.3)
   Local and distant               5 (2.5)                0 (0)
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Characteristic, n (%) / median (IQR) No IV Iron (n = 83) IV Iron  (n = 83) p value
Male gender 38 (45.8) 45 (54.2) 0.28
age, years 72 (66-79) 75 (67-80) 0.38
tumor location 0.48
Colon 71 (85.5) 74 (89.2)
rectum 12 (14.5) 9 (10.8)
aSa 0.87
1-2 54 (65.1) 55 (66.3)
3-4 29 (34.9) 28 (33.7)
treatment approach 0.72
Open 19 (22.9) 21 (25.3)
Laparoscopic 64 (77.1) 62 (74.7)
resection 0.76
    (extended) right colectomy/transversum 50 (60.2) 51 (61.4)
    (extended) left colectomy 9 (10.8) 8 (9.6)
    Sigmoid resection/low anterior resection /abdominoperineal resection 23 (27.7) 21 (25.3)
    Other 1 (1.2) 3 (3.6)
aJCC tNM stage 0.42
1-2 54 (65.1) 49 (59.0)
3-4 29 (34.9) 34 (41.0)
Distant metastases 5 (6.0) 6 (7.2) 0.76
Dose intravenous iron
   1000mg - 55 (66.3)
   2000mg - 28 (33.7)
Blood transfusion 16 (19.5) 12 (14.5) 0.39
hb at diagnosis (mmol/L) 6.4 (5.7-7.1) 6.3 (5.7-7.1) 0.89
recurrent disease (excluding M+ patients) 16 (20.5) 9 (11.4)
   Distant                15 (19.1)              8 (10.1)
   Local and distant                1 (1.3)     1 (1.3)
Table 3. Propensity score matched baseline characteristics, IV iron versus no IV iron












Characteristic, n (%) / median (IQR) No Event (n = 49) Event (n = 28) p value
Male gender 25 (51.0) 15 (53.6) 0.83
age, years 72 (67-79) 79 (73-82) 0.009
tumor location 0.65
Colon 44 (89.8) 26 (92.9)
rectum 5 (10.2) 2 (7.1)
aSa 0.25
1-2 36 (73.5) 17 (60.7)
3-4 13 (26.5) 11 (39.3)
treatment approach 0.053
Open 8 (16.3) 10 (35.7)
Laparoscopic 41 (83.7) 18 (64.3)
resection 0.39
    (extended) right colectomy/transversum 35 (71.4) 17 (60.7)
    (extended) left colectomy 4 (8.2) 3 (10.7)
    Sigmoid resection/low anterior resection /abdominoperineal resection 9 (18.4) 5 (17.9)
    Other 1 (2.0) 3 (10.7)
aJCC tNM stage 0.65
1-2 34 (68.0) 18 (56.2)
3-4 15 (30.6) 10 (35.7)
Distant metastases 1 (2.0) 1 (3.6) 0.69
preoperative blood transfusion 6 (12.2) 6 (21.4) 0.29
Iron status at diagnosis
    hb (mmol/L) 6.0 (5.5-7.1) 5.9 (5.3-6.9) 0.35
    Ferritin (μg/L) 23.0 (9.5-81) 47.5 (13.0-131.0) 0.31
    transferrin (g/L) 2.83 (2.57-3.23) 2.53 (1.99-3.07) 0.052
    tSat (%) 8.93 (4.11-16.27) 6.57 (4.49-15.27) 1.00
Table 4. Baseline characteristics of IV iron patients, event (death of recurrence) versus no event at minimum follow up 
of 2.5 years 
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In the propensity matched intravenous iron group, the mean OS was 58 months and the estimated 
1-, 3- and 5-year OS was 91.6%, 73.1%, and 64.3%, respectively, which was comparable with the 
matched non-intravenous iron group (p=0.456)(fig. 1). Mean DFS was 58 months in the matched 
intravenous iron group, with estimated 1-, 3- and 5-year DFS of 94.5%, 86.7%, and 83.4%, which did 
not differ from the matched non-intravenous iron group (p=0.240; fig 2). In addition to the survival 
curves, no significant difference was observed in the time to recurrence between the intravenous 
iron (13.8 months; 10.3-21) and the non-intravenous iron group (13.3 months; 8.0-19.8, p=0275)
(fig. 3).
For more detail on the iron status as potential predictive factor for long-term survival in patients 
receiving preoperative intravenous iron therapy, all patients in the intravenous iron group and 
with a minimum follow up of 2.5 years were divided in an event (i.e. death of recurrence) and a 
non-event group (table 4). In baseline characteristics, only age was significantly different between 
both groups (event 79 (73-82) vs no event 72 (67-79), p=0.009). regarding gender, tumor location, 
ASA classification, TNM stage, treatment approach and resection type, no significant differences 
were observed. With regard to iron status, TSAT was equal in both groups (event 6.6 (4.5-15.3) 
vs no event 8.9 (4.1-16.3), p=1.00), while a trend was found for decreased transferrin in the event 
group (2.53 (1.99-3.07) vs 2.83 (2.57-2.23), p=0.052). Ferritin was increased in the event group, but 
statistical significance was not reached (47.5 (13.0-131.0) vs 23.0 (9.5-81.0), p=0.3).
dIscussIon
the present study shows that a dose of 1000-200mg preoperative intravenous iron therapy does 
not have a distinct effect on long-term overall and disease-free survival in anemiccolorectal 
cancer patients. In addition, in all patients with recurrent disease, intravenous iron therapy did 
not negatively affect the time to recurrence. On the other hand, long-term benefits, as were hoped 
for, were neither observed. Interestingly, in assessing the predictive value of iron status in patients 
receiving intravenous iron therapy, decreased transferrin, and to lesser extent increased ferritin, 
emerge to be potentially associated with impaired long-term survival. 
elemental iron is involved in numerous biological and cellular processes such as DNa synthesis, 
oxygen transport and cellular growth, and therefore is an essential nutrient for mammalian life.21, 
26 Clinically, the presence of preoperative anemia and the often-associated iron deficiency results 
in fatigue and impaired physical performance. Most important, however, anemia was found to 
be associated with increased postoperative morbidity and mortality.3-5 the use of blood transfu-
sions to treat the anemia, paradoxically and possibly due to transfusion-related immunomodula-
tion (trIM), however, was reported to be independently associated with impaired postoperative 
outcome in colorectal cancer patients.6, 7 these data, combined with the high prevalence of iron 
deficiency anemia in these patients12, explains why at present iron therapy is regarded as the most 
logical, and intravenous iron therapy as the most efficient way to optimise preoperative hb level. 












The greater efficacy of intravenous iron is to a great extent explained by the high prevalence of 
anemia of chronic disease (or functional iron deficiency anemia) in colorectal cancer patients.2 
While several cohort studies have indeed already demonstrated that intravenous iron therapy is 
positively influencing short-term outcomes with optimisation of hb level and reduction of blood 
transfusion use14-16, our study is the first to focus on possible effects of iron on long-term outcomes.
In this regard, it is important to realise that iron could be potentially harmful. as indicated, iron 
mediates free radical formation and it regulates crucial cell proliferation signaling pathways, 
including the Wnt pathway, in tumors.27 therefore, excess iron can contribute to both tumor 
initiation and tumor growth, demonstrated by several experimental animal studies 18, 28, 29, and 
supported by epidemiological studies showing the association between high body iron stores 
and increased cancer risk.19, 20 
Figure 1. Overall survival stratified for intravenous iron treatment group 
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Figure 2. Disease-free survival stratified for intravenous iron treatment group  
In addition to the role of iron in tumor initiation and tumor growth, another potential argument 
against the use of intravenous iron therapy in anemiccolorectal patients is the indistinctness of 
the causal relationship between anemia and blood transfusion on the one hand, and impaired 
postoperative outcome (i.e. morbidity and mortality) on the other. a paucity of evidence exists on 
this causality, and this is stressed by recent meta-analyses investigating the prognostic factor of 
preoperative anemia and blood transfusions4-6. Moreover, a randomised controlled trial failed to 
demonstrate that at long-term follow up colorectal cancer patients did benefit from autologous 
transfusion (i.e. no transfusion-related immunomodulation) as compared with standard 
allogeneic transfusion.30 Question this causality between anemia and survival, the legitimate 
question arises as to whether correction of preoperative anemia, independent of therapy, will ever 
positively influence outcome or that anemia simply is a marker of the severity of the underlying 
disease. Causing harm by correction of the anemia should by all means be avoided.












Figure 3. Time to recurrence (months), intravenous iron versus no intravenous iron
Assessing the type of iron deficiency anemia might be an additional important variable in studying 
the long-term effect of intravenous iron therapy. Chronic blood loss, as can be envisioned by 
bleeding from gastrointestinal tumors, in this respect causes absolute iron deficiency (AID), 
characterised by depleted iron stores. Functional iron deficiency (FID), in contrast, is caused 
by impaired iron homeostasis and is, due to increased hepcidin production, characterised by 
reduced iron uptake and iron mobilisation from the reticulo-endothelial system. Despite definite 
evidence, FID in this respect could be regarded as a potentially effective defence strategy to 
inhibit growth of pathogens and tumor cells.13 Interestingly, some support for this hypothesis 
could be found in our results, showing that lower transferrin and higher ferritin levels, markers for 
functional iron deficiency, were associated with decreased long-term survival after iron therapy. 
however, an important note of caution is due here since the event and non-event group were not 
completely comparable (i.e. significant difference for age) and since ferritin and transferrin values 
were not significantly different between both groups.
strength And lIMItAtIons
the key strength of present study is that it is the first to focus on the effect of intravenous iron 
therapy on long-term survival in colorectal cancer patients. Despite a growing body of epidemio-
logical and animal studies stressing the eminent role of iron in cancer development and cancer 
growth, till now no studies addressed the safety of intravenous iron therapy in a clinical cohort. 
Although of retrospective nature, the baseline differences between the intravenous and non-intra-
venous iron group were corrected for by propensity score matching. this enabled us to properly 
calculate survival estimates using the Kaplan-Meier method. Finally, due to the propensity score 
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matching, the most important confounding factors of intravenous iron therapy, hb level at 
diagnosis and blood transfusions, were equal in both groups. Median follow up duration of 47 
months was sufficiently long. 
The major limitations of this study derive from its retrospective nature and its small sample size. 
Over the course of the study period, preoperative intravenous iron therapy was administered more 
frequently in anemicpatients. This treatment was mostly depending on the clinical assessment, 
and on the knowledge of patient blood management of each individual physician. Increased 
knowledge of patient blood management probably have caused the increased administration of 
intravenous iron therapy. In this respect, selection bias, inherent to a retrospective cohort study, 
might have affected the outcome. We attempted to minimize this selection bias by propensity 
score matching for several important prognostic factors, however, possible confounders may be 
hidden and therefore selection bias cannot be completely ruled out. In assessing the predictive 
value of iron status in patients receiving intravenous iron therapy (table 4), the small sample size 
did not allow us to correct for the variable of age, which was significantly different between the 
event and no event group. In addition, we were not able to study the dose-response relationship. 
Finally, we focused on the surgical patient and by doing so, the legitimate question could arise 
as to whether surgery and tumor eradication might neutralise the possible detrimental effects of 
intravenous iron on tumor growth and long-term prognosis. Future studies should therefore also 
address non-surgical patients.
conclusIon
Despite a growing body of epidemiological and experimental studies stressing the important role 
of iron in cancer development and cancer growth, the present study shows that preoperative 
intravenous iron therapy does not have a profound effect on long-term overall and disease-free 
survival in anemiccolorectal cancer patients. Future randomised trials with sufficient power are 
required to draw definite conclusions on the safety of intravenous iron therapy, and to further 
investigate the predictive value of type of iron deficiency, to establish the dose-response relation-
ship, and to study the safety of intravenous iron therapy in non-surgical patients. 
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General discussion
anemia is a common finding in cancer patients and is observed in up to 40 percent of the 
patients diagnosed with colorectal cancer.1 Whilst preoperative anemia has been established 
as an independent risk factor for adverse short-term outcome following colorectal cancer 
surgery,2 such as an increased number of complications and a longer hospital stay, studies on 
the association between preoperative anemia and long-term cancer outcome show inconsist-
ent results. It has been hypothesized that anemia impairs long-term prognosis via worsening 
of tumor hypoxia, which is linked to radiotherapy and chemotherapy resistance.3-5 In addition, 
by inducing proteomic and genomic changes, hypoxia may also increase the proliferative and 
metastatic potential.3  Due to the inconsistencies demonstrated by various studies, we conducted 
a systematic review and meta-analysis to assess the long-term prognostic value of preoperative 
anemia in colorectal cancer patients (chapter 2). In meta-analyses including both colon and rectal 
cancer patients, preoperative anemia was significantly associated with decreased overall survival 
(HR 1.56, 95% CI 1.30 to 1.88) and disease-free survival (HR 1.34, 95% CI 1.11 to 1.61). However, 
when restricted to studies exclusively on colon or rectal cancer patients, analyses demonstrated 
that preoperative anemia is only significantly associated with decreased long-term overall and 
disease-free survival in rectal cancer patients, and not in colon cancer patients. Following the 
results of this meta-analysis, raised awareness about the impact of preoperative anemia on 
long-term survival is justified, but it remains uncertain whether anemia is an independent risk 
factor for impaired long-term survival or just a marker of the severity of co-morbid disease. 
Causes of anemia in patients with colorectal cancer are often multifactorial. Anemia may 
be attributed to the underlying disease or to therapy-related factors. At diagnosis, however, 
anemia most often results from iron deficiency (i.e. absolute or functional). The prevalence of 
iron deficiency is reported to be approximately 50 percent in colorectal cancer patients.6 The 
malignancy itself can lead to this iron deficiency in two major ways. Firstly, cancer cells can 
produce cytokines that lead to increased hepcidin production by the liver, inducing reduced 
duodenal iron uptake as well as iron mobilization from the reticulo-endothelial system. These 
effects lead to a functional iron deficiency, often referred as anemia of chronic disease or anemia 
of inflammation.7 In this condition, the amount of stored iron is sufficient, but the bioavailable 
iron necessary for erythroblast production is deficient. Secondly, chronic blood loss at tumor site 
can deplete iron stores and cause an absolute iron deficiency anemia. Identification of the type 
of iron deficiency is of major importance because both types of iron deficiency are recommended 
to be treated differently.8, 9 Whereas iron is recommended for patients who develop absolute iron 
deficiency, it is not recommended for patients who develop functional iron deficiency as a result 
of disease-related factors (i.e. infection or inflammation).9 Oral iron in these patients namely is 
ineffective, as hepcidin blocks the duodenal iron uptake and thus the subsequent iron transport 
to the bone marrow. 












Our retrospective study in chapter 3 demonstrated that the prevalence of iron deficiency is ap-
proximately 50 percent in all colorectal cancer patients, and 80 percent in anemic colorectal 
cancer patients. This result is in accordance with the prevalence observed in a previous study.6 
In regard of the type of iron deficiency, the vast majority was a combination of absolute and 
functional iron deficiency (81.0%); only 3.7% and 15.3% was an isolated absolute and isolated 
functional iron deficiency, respectively. The clinical relevance of iron deficiency in our patient 
cohort, however, was disputable, as only severe iron deficiency was significantly associated with 
increased postoperative complication rate in a univariate analysis. 
Elaborating on the observed prevalence numbers of (type of) iron deficiency, we decided to 
perform a national survey to assess the current preoperative blood management strategies in 
the Netherlands, and to determine whether the recommendations formulated in international 
oncological guidelines are being followed. The concept of patient blood management (PBM) has 
been developed to promote ‘the appropriate provision and use of blood, its components and 
derivatives, and strategies to reduce or avoid the need for a blood transfusion.10 Special focus 
in PBM has been the early identification and treatment of preoperative anemia, the strongest 
indicator for perioperative blood transfusion. Moreover, there is an increasing awareness of the 
need and also a debate on how to integrate patient blood management within routine surgical 
care, resulting in numerous ongoing trials studying the optimal blood management strategy 
in all types of surgery, including colorectal cancer surgery.11-13 Results of our survey among 
surgeons, gastroenterologists and anesthesiologists, as shown in chapter 4, demonstrated a 
distinct variability in preoperative blood management practices. Strikingly, this variability was 
not only seen between, but also within Dutch hospitals, as indicated by the varying responses 
from surgeons, gastroenterologists and anesthesiologists. In general, poor compliance with the 
recommendations in international guidelines on the management of anemia in cancer patients 
was observed. This was for example illustrated by the low number of hospitals in which iron status 
was measured during screening for colorectal cancer (i.e. less than 40 percent), crucial to identify 
the type of anemia and to determine the optimal treatment.
As anemia is most frequently iron-deficient in etiology, iron supplementation is regarded as a 
feasible technique to optimize hemoglobin level and minimize the use of blood transfusion, 
which itself has been independently associated with worse patient outcome, as demonstrated 
in multiple randomized trials.14-18 In this regard, the effect of intravenous iron, in opposition to 
oral iron, is increasingly being explored. Compared to the side effects present in the majority of 
people taking oral iron preparations, the side effects with intravenous iron are minor, infrequent 
and short-lasting.19 Early intravenous iron preparations were associated with a high rate of 
serious adverse events, most notably anaphylactic shock. Newer formulations, which bind the 
elemental iron more tightly resulting in a much slower release, are found to be much safer.20 With 
this improved short-term safety of intravenous iron preparations, the efficacy of intravenous iron, 
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in terms of optimizing hemoglobin level and reducing the need for blood transfusions, received 
new interest.11, 12 Although all previous studies consistently demonstrated that intravenous iron, 
as compared to oral iron or placebo, is more effective in treating preoperative anemia, inconsist-
ent results are observed in reducing the blood transfusion requirement.12, 18, 21, 22 While none of the 
previous studies identified characteristics/biomarkers associated with the magnitude of response 
in raising hemoglobin level, our results demonstrated that intravenous iron therapy is most 
effective in patients presenting with more severe anemia, and with higher transferrin and lower 
ferritin levels (chapter 5). Our results failed to demonstrate that the distinct hemoglobin increase 
after iron infusion leads to a decreased proportion of patients with a postoperative complica-
tion and/or blood transfusion. Following our results, we believe future studies on the short-term 
efficacy of intravenous iron should take the type of anemia/iron deficiency (i.e. absolute or 
functional iron deficiency) into account when studying the potential blood transfusion reducing 
effect. 
Supported by data on the short-term safety and efficacy, many studies advocate a more 
prominent role for intravenous iron therapy in preoperative/patient blood management.20, 23 
However, before intravenous iron should be considered as the default therapy to treat a mild to 
moderate preoperative anemia in cancer patients, well-designed trials are required to evaluate 
the long-term effects and safety. By introducing intravenous iron as a therapy to reduce the blood 
transfusion requirement, it is essential to extensively investigate all safety aspects of intravenous 
iron, including the long-term effects, and to compare these results to those of blood transfusion. 
These long-term oncological effects of iron therapy are of special interest, as the results of 
laboratory, epidemiological and animal studies have shown iron’s role in all aspects of cancer 
development and cancer growth.24-29 Iron is an essential nutrient participating in numerous 
biological and cellular processes, facilitating normal cell proliferation and growth. Results of ex-
perimental studies moreover demonstrated that iron therapy is also able to enhance colorectal 
tumor growth and might contribute to an increased metastatic potential.25, 26, 30 In addition, many 
transport proteins that were originally studied for their roles in normal iron metabolism have 
now been shown to also contribute to malignant tumor growth. Compared to non-malignant 
colon cells, iron import proteins, such as DMT1 and TfR1, are upregulated, while ferroportin, the 
only known iron export protein, is downregulated in colon tumor cells, seemingly subverting the 
normal homeostatic control into a chronic iron acquisition state enabling enhanced prolifera-
tion.31-33 Hypothetically, as extension of these data, anemia of inflammation could be regarded 
as a potentially effective defense strategy of the human body to limit the growth of tumor cells.7 
In this respect, due to increased hepcidin production, iron is sequestered from tumor cells into 
the reticuloendothelial system, resulting in a limitation of the availability of iron for the growth 
of tumor cells. In agreement, the avidity of cancer cells for iron has also led to the question of 
whether iron chelators could be used as anticancer therapy. Iron chelators, such as desferriox-
amine (DFO), were initially designed to prevent iron-mediated toxicity in patient with hemoglo-












binopathy. The potential of iron chelators as anticancer therapy first came to light in studies 
assessing the anticancer effect of iron chelators in experimental studies,34-37 and ever since, there 
is a growing interest in iron chelators as anticancer therapy. To date, promising clinical results 
are demonstrated in patients with hepatocellular cancer,38 prompting future research to iron 
chelators as a new iron-directed anticancer therapeutic.
Supported by all abovementioned circumstantial evidence, we hence decided to explore the 
effect of preoperative intravenous iron therapy on colorectal tumor prognosis in a matched 
cohort study (chapter 7). Our study failed to demonstrate that preoperative intravenous iron 
therapy has a profound effect on long-term overall and disease-free survival in anemic colorectal 
cancer patients. However, it should be stressed that the results were derived from a small-sized 
retrospective study, and therefore should be interpreted with caution. 
To conclude, the high prevalence of iron deficiency and associated anemia in our colorectal 
cancer patient group often involves a functional hepcidin-mediated iron deficiency. This stresses 
the particular potential of preoperative intravenous iron therapy to 1) optimize hemoglobin level, 
namely in patients with more severe anemia and with higher transferrin and lower ferritin levels, 
and 2) reduce the blood transfusion requirement. In this respect, intravenous iron might benefit 
the patient by reducing the blood transfusion and anemia-related adverse effects. However, to 
date, only our small-sized retrospective study has addressed the long-term effects of preoperative 
intravenous iron therapy in colorectal cancer patients, showing no profound effect. Therefore, 
new well-designed trials studying the possible long-term effects of intravenous iron are required 
to answer the question whether the use of intravenous iron as first-line/default therapy to treat a 
mild to moderate preoperative anemia is a safe strategy for oncological patients.
Future perspectives: new iron-directed diaGnostics and 
therapeutics
Assessment of the long-term effects of iron therapy is needed to identify the optimal blood 
management strategy in colorectal cancer patients, and therefore, we believe future research 
should put more focus on this subject. Proper assessment of such long-term effects can be 
achieved by different means. 
Firstly, the long-term effects can be monitored in an observational cohort study, as demon-
strated in this thesis. However, this study design involves significant limitations. In a cohort 
study, significant differences between an iron-treatment and non-iron treatment group (e.g. 
hemoglobin levels and administration of blood transfusion) would, despite possible matching, 
likely introduce selection bias or confounding by indication, and significantly affect outcome. 
Therefore, to eventually demonstrate a potential causal relationship between iron therapy and 
long-term survival, randomized controlled trials should be considered. Randomized controlled 
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trials avoid selection bias and are the gold standard for establishing causal conclusions. However, 
in studying the effect of iron therapy, we believe that it is of importance to not only look at clinical 
endpoints, such as long-term overall and disease-free survival, but also, more specific and in 
line with many in vitro and animal studies, to look at what extent iron might enhance tumor 
growth, and, importantly, which colorectal tumor phenotypes are ‘iron-hungry’ for their growth. 
We strongly believe a more patient and tumor specific approach is required, and therefore, a 
comprehensive picture of exactly how iron metabolism is altered in malignant cells is needed. 
This namely will determine how iron therapy, or even iron chelation therapy, might influence the 
tumor itself. For this purpose, new and feasible methods to assess the iron content in colorectal 
tumors should be explored and be implemented.
To date, multiple experimental studies have already shown the possibility of quantifying iron 
and assessing the gene and protein expression levels of iron transporters in colorectal cancer 
specimens/samples. Evidently, the main disadvantage of these experiments is that surgery 
or biopsy is required in order to enable direct iron assessment in tumor samples. As a non-in-
vasive alternative, novel diagnostic methods to visualize and quantify iron-rich biochemical 
compounds are being explored.39, 40 As an example, a novel magnetic resonance protocol might 
allow reliable preoperative quantification of iron in colorectal tumors and is presently studied. 
This novel and non-invasive proton magnetic resonance spectroscopy (H-MRS) should of course 
first be validated against the actual iron content in tumor samples. If the novel scanning method 
provides high diagnostic accuracy for the assessment of iron load in colorectal tumors, it is the 
first demonstration of a non-invasive iron-directed test with the possibility to 1) quantity the iron 
load in colorectal tumors, 2) assess the effect of iron therapy on iron load in the tumor, and 3) to 
identify iron-dependent and non-iron dependent colorectal tumors, and 4) to investigate whether 
different treatments in different phenotypes could change the prognosis. 
Apart from studying the effects of iron therapy by H-MRS, assessing the optimal management 
of anemia in colorectal cancer patients may be even more challenging. For this purpose, the 
detrimental long-term effects of iron treatment must be compared with those of not only anemia, 
but also with alternatives to treat anemia like ESAs and more important also blood transfusions. 
The problem here is that a head-to-head comparison of blood transfusion and iron therapy 
might be impossible in the clinical setting. The indications for both therapies are namely clearly 
different. While iron therapy is indicated and used in patients with a mild to moderate anemia, 
blood transfusions are only administered in case of severe anemia. To still assess the optimal 
management of anemia, animal experiments could be considered. In a colorectal cancer rodent 
model, the effect on tumor growth of both anemia, blood transfusion and iron therapy (both oral 
and intravenous) could be accurately assessed and compared. 
The abovementioned animal and H-MRS studies will provide a more detailed understanding of 












the oncological effect of iron therapy, enabling the identification of high- and low-risk patients 
for iron therapy. Based on these studies, the execution of a prospective randomized trial should 
be considered to test the effect of iron therapy on long-term survival. In such a trial, preopera-
tive anemic patients should be randomized into an iron-treatment and a non-treatment group. In 
designing a study protocol, multiple important issues should be taken into consideration. 
Firstly, in conducting a prospective trial randomizing anemic patients in an iron-treatment and a 
non-treatment group, it could be held unethical to have a non-treatment group because anemia 
itself is considered as a major risk factor for impaired disease-free and overall survival in cancer 
patients.  As a first alternative, iron therapy could be considered in all anemic patients, subdivided 
into patients with iron-dependent and non-iron dependent colorectal tumor phenotypes. 
Assessment of the iron-dependency of the tumor could be, potentially, done by the novel 
scanning method and by identification of protein expression levels of iron transporters and iron 
itself in tumor samples. We hypothesize that iron therapy will show to be especially hazardous in 
patients with an iron-dependent tumor. As a second alternative, all patients with a non-anemic 
iron deficiency could be randomized into an iron-treatment and a non-treatment group.
Secondly, the dose-response relationship and the administration route (oral versus intravenous) 
should be considered. Often, the conditions in experimental studies, demonstrating the tumor-
growing effect of iron, do not properly reflect the situation in anemic patients using excessive 
iron doses in iron-replete animals. In addition and of special interest, colorectal cancer animal 
models studying the effect of intravenous iron administration have so far not been published. 
In humans, particularly the effect of intravenous iron is of special interest as intravenous iron is 
presently more frequently being used as compared to oral iron.
Thirdly, as cancer types are shown to be iron-dependent, one might not only refrain from iron ad-
ministration, but, apart from the presence of anemia or complete surgical eradication, even add 
iron chelation. In addition to iron chelation, two other iron-directed therapeutics can be explored. 
First, antibodies targeted towards the transferrin receptor 1 (TFR1) that effectively deplete intra-
cellular iron are being studied. These antibodies have shown to effectively antagonize the growth 
of leukemia in mice.41 Second, hepcidin-targeted treatment approaches, aiming at increasing 
ferroportin or decreasing local hepcidin levels, are being under investigation. The hepcidin 
depletion could be realized by neutralizing antibodies or hepciding small interfering RNAs.42-44
Additionally to all above, also the study of non-surgical patients should be deliberated. By focusing 
on only preoperative patients, the legitimate question could arise as to whether surgery and 
resection of the tumor might neutralize the possible detrimental effect of iron therapy on tumor 
growth and long-term prognosis. Therefore, future research studying the effect of iron therapy 
should also consider patients with premalignant colorectal adenomas.    
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In chapter 1 a general outline of this thesis is given and the topic of perioperative blood 
management is introduced with a special focus on the detrimental effects of anti-anemic 
therapies and the role of iron in colorectal cancer patients. 
Anemia is a common finding in cancer patients and is observed in up to 40 percent of the patients 
diagnosed with colorectal cancer. It has been hypothesized that anemia impairs long-term 
prognosis via worsening of tumor hypoxia, which is linked to radiotherapy and chemothera-
py resistance. In chapter 2 the results of a systematic review and meta-analysis assessing the 
long-term prognostic value of preoperative anemia in colorectal cancer patients are presented. In 
meta-analyses including both colon and rectal cancer patients, preoperative anemia was signifi-
cantly associated with decreased overall survival (HR 1.56, 95% CI 1.30 to 1.88) and disease-free 
survival (HR 1.34, 95% CI 1.11 to 1.61). However, when restricted to studies exclusively on colon 
or rectal cancer patients, analyses demonstrated that preoperative anemia is only significantly 
associated with decreased long-term overall and disease-free survival in rectal cancer patients, 
and not in colon cancer patients. 
In chapter 3 an overview of the prevalence and treatment of preoperative iron deficiency in 
colorectal cancer patients is provided. In approximately 50 percent of all colorectal cancer 
patients, and 80 percent of anemic colorectal cancer patients, iron deficiency is observed. 
In regard of the type of iron deficiency, the vast majority was a combination of absolute and 
functional iron deficiency (81.0%); only 3.7% and 15.3% was an isolated absolute and isolated 
functional iron deficiency, respectively. The clinical relevance of iron deficiency in our patient 
cohort, however, was disputable, as only severe iron deficiency was significantly associated with 
increased postoperative complication rate in a univariate analysis. 
results of a survey among surgeons, gastroenterologists and anesthesiologists to assess the 
preoperative blood management strategy in colorectal cancer patients in Dutch hospitals 
are presented in chapter 4. a distinct variability in preoperative blood management practices 
was demonstrated. Strikingly, this variability was not only seen between, but also within Dutch 
hospitals, as indicated by the varying responses from surgeons, gastroenterologists and anesthe-
siologists. In general, poor compliance with the recommendations in international guidelines on 
the management of anemia in cancer patients was observed. this was for example illustrated by 
the low number of hospitals in which iron status was measured during screening for colorectal 
cancer (i.e. less than 40 percent), crucial to identify the type of anemia and to determine the 
optimal treatment.
In chapter 5 the short-term effect of preoperative intravenous iron therapy is studied in a 
cohort study. Preoperative intravenous iron therapy is most effective in patients presenting 
with more severe anemia, and with higher transferrin and lower ferritin levels. the results failed 












to demonstrate that the distinct hemoglobin increase after iron infusion leads to a decreased 
proportion of patients with a postoperative complication and/or blood transfusion. 
In chapter 6 the long-term safety of preoperative intravenous iron therapy is being questioned. 
the hypothesis that iron therapy as treatment of anemia could be a potentially detrimental and 
hazardous strategy in colorectal cancer patients is elaborated. 
Supported by the hypothesis in chapter 6, the effect of preoperative intravenous iron therapy 
on long-term survival in anemic colorectal cancer patients is studied in a matched cohort study 
in chapter 7. the study failed to demonstrate that preoperative intravenous iron therapy has 
a profound effect on long-term overall and disease-free survival in anemic colorectal cancer 
patients. However, it should be stressed that the results were derived from a small-sized retro-
spective study, and therefore should be interpreted with caution.
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IIn hoofdstuk 1 wordt een algemene schets van dit proefschrift gegeven en wordt het onderwerp
peri-operatief bloedbeleid geïntroduceerd met speciale aandacht voor de schadelijke effecten
van anti-bloedarmoede therapieën en de rol van ijzer bij patiënten met dikkedarmkanker.
Bloedarmoede is een veel voorkomende bevinding bij kankerpatiënten en wordt waargenomen 
bij maximaal 40 procent van de patiënten met dikkedarmkanker. er werd verondersteld dat bloed-
armoede de langetermijnprognose schaadt door verergering van het zuurstoftekort van de tumor, 
wat verband houdt met resistentie tegen bestraling en chemotherapie. In hoofdstuk 2 worden 
de resultaten gepresenteerd van een systematische review en meta-analyse van de langetermijn 
prognostische waarde van pre-operatieve bloedarmoede bij patiënten met dikkedarmkanker. In 
meta-analyses met zowel colon- als rectumkankerpatiënten, was preoperatieve bloedarmoede 
significant geassocieerd met een afname van de algehele overleving (HR 1,56, 95% CI 1,30 tot 1,88) 
en ziektevrije overleving (HR 1,34, 95% betrouwbaarheidsinterval 1,11 tot 1,61). Echter, wanneer 
beperkt tot studies met uitsluitend colon- of rectumkankerpatiënten, toonden analyses aan dat 
preoperatieve bloedarmoede alleen significant geassocieerd is met een verminderde algemene 
en ziektevrije overleving op de lange termijn bij patiënten met rectumkanker, en niet bij patiënten 
met colonkanker.
In hoofdstuk 3 wordt een overzicht gegeven van de prevalentie en behandeling van pre-operatieve 
ijzerdeficiëntie bij patiënten met dikkedarmkanker. In ongeveer 50 procent van alle patiënten met 
dikkedarmkanker werd ijzerdeficientie geobserveerd. Dit percentage lag op 80% bij patiënten met 
dikkedarmkanker en bloedarmoede. Met betrekking tot het type ijzerdeficiëntie was de overgrote 
meerderheid een combinatie van absolute en functionele ijzerdeficiëntie (81,0%); slechts 3,7% 
en 15,3% was een geïsoleerde absolute en geïsoleerde functionele ijzertekort, respectievelijk. 
De klinische relevantie van ijzerdeficiëntie in ons patiëntencohort was echter discutabel, omdat 
alleen ernstige ijzerdeficiëntie in een univariate analyse significant geassocieerd was met een 
verhoogd postoperatief complicatiepercentage.
Resultaten van een onderzoek onder chirurgen, gastro-enterologen en anesthesiologen om de 
preoperatieve strategieën voor bloedbeleid bij patiënten met dikkedarmkanker in Nederlandse 
ziekenhuizen te achterhalen, worden gepresenteerd in hoofdstuk 4. een duidelijke variabiliteit 
in pre-operatief bloedbeleid werd aangetoond. Opvallend was dat deze variabiliteit niet alleen 
tussen, maar ook binnen Nederlandse ziekenhuizen werd waargenomen, zoals blijkt uit de uiteen-
lopende reacties van chirurgen, gastro-enterologen en anesthesiologen. Over het algemeen werd 
een slechte naleving van de aanbevelingen in internationale richtlijnen over de behandeling van 
bloedarmoede bij kankerpatiënten waargenomen. Dit werd bijvoorbeeld geïllustreerd door het 
lage aantal ziekenhuizen waarin de ijzerstatus werd gemeten tijdens screening op colorectale 
kanker (d.w.z. minder dan 40%), cruciaal om het type bloedarmoede te identificeren en om de 
optimale behandeling te bepalen.












In hoofdstuk 5 wordt het kortetermijneffect van pre-operatieve intraveneuze ijzertherapie 
bestudeerd in een cohortonderzoek. pre-operatieve intraveneuze ijzertherapie is het meest 
effectief bij patiënten met ernstigere bloedarmoede en met hogere transferrine- en lagere fer-
ritinespiegels. De resultaten lieten niet zien dat de duidelijke hemoglobinestijging na ijzerinfusie 
leidt tot een verminderd aantal patiënten met een postoperatieve complicatie en / of bloedtrans-
fusie.
In hoofdstuk 6 wordt de veiligheid op lange termijn van pre-operatieve intraveneuze ijzertherapie
in twijfel getrokken. De hypothese dat ijzertherapie als behandeling van bloedarmoede een 
potentieel schadelijke en gevaarlijke strategie zou kunnen zijn bij patiënten met dikkedarmkank-
er, is uitgewerkt.
Ondersteund door de hypothese in hoofdstuk 6, wordt het effect van pre-operatieve intraveneuze
ijzertherapie op de langetermijnoverleving bij patiënten met dikkedarmkanker en bloedarmoede 
bestudeerd in een gematchte cohortstudie in hoofdstuk 7. het onderzoek kon niet aantonen dat
pre-operatieve intraveneuze ijzertherapie een diepgaand effect heeft op lange termijn algehele en
ziektevrije overleving bij patiënten met dikkedarmkanker en bloedarmoede. er dient echter te 
worden benadrukt dat de resultaten zijn afgeleid van een retrospectief onderzoek van kleine 
omvang en daarom met de nodige voorzichtigheid geïnterpreteerd moeten worden.
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